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ABSTRACT 
Haematopoietic stem cell transplantation (HSCT) is a complicated and high-risk procedure used 
to cure disease or stop the spread of disease in a range of cancers. HSCT carries a high incidence 
of mortality and is associated with distressing short and long-term side effects. In addition, 
patients remain at risk of recurrence or mortality years after transplantation. Therefore, patients 
undergoing HSCT have been found to experience significant emotional and psychosocial distress 
because of the trauma associated with treatment. The literature suggests that about 50% of HSCT 
patients will experience clinical levels of distress. Carers and family members play an important 
role in caring for these ill patients in the short and long-term. Major role changes and financial 
stressors are experienced in many families, adding to the burden of care. However, very little is 
known about the rates of psychopathology in carers of HSCT patients.  
 
Due to the arduous nature of HSCT, psycho-educational programmes have been developed by 
major transplant centres and hospitals in order to provide HSCT patients and their families with 
information on the treatment process, side effects, risks, and long-term outcomes. Research on 
patient education in oncology has shown that providing patients and carers with information 
about their illness and treatment reduces anxiety and distress. To date, there have been no 
empirical evaluations to support the use of education programmes for HSCT patients. While it 
could be assumed that information would be helpful in reducing anxiety and depression in HSCT 
as it is in oncology generally, the information provided to these patients is usually more 
confronting and therefore, may be less reassuring. Thus, it is not known whether providing 
patients with education about HSCT reduces patient and carer distress or whether it might 
actually increase adverse outcomes. 
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The aim of the present study was to evaluate the rates and correlates of distress in carers and 
patients and examine the effect of a psychoeducation programme for patients undergoing HSCT 
and their carers on knowledge, distress, information satisfaction, social support and caregiver 
burden. A randomised control trial was conducted to provide empirical data in relation to the 
latter aim. The following hypotheses were proposed. Firstly, it was hypothesised that patients 
and carers who received the education programme would have higher levels of knowledge, not 
evidenced in a group waiting to receive the programme. Secondly, it was hypothesised that the 
education program would not lead to increased anxiety and depressive symptoms. Thirdly, 
patients who know more about their condition would be the least distressed. As predicted, this 
study found high levels of distress, particularly in carers. Higher patient distress was related to 
having more concern about one’s illness and experiencing more symptoms. Education was 
effective in increasing patient and carer knowledge. Importantly there were no adverse effects of 
knowledge and greater patient knowledge following the education program was associated with 
less distress, although there was no direct effect of education on distress. Future research should 
aim to identify what aspects of the education program are helpful to patients. Finally, support 
interventions such as CBT are needed to help patients and carers, in particular, cope with the 
high levels of distress inherent in the HSCT experience. 
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OVERVIEW 
This thesis is structured into two separate studies with four chapters. Chapter 1 reviews the 
current literature on Haematopoietic Stem Cell Transplantation, patient and carer 
psychopathology, informed consent and patient and carer education. It also provides a rationale 
for the thesis. Chapter 2 reports the rates and correlates of distress in patients and carers from the 
baseline assessment of the main study (reported in Chapter 3). The results of this study 
demonstrated high rates of distress, particularly for carers of HSCT patients. The randomised 
controlled trial of the education programme is presented in Chapter 3. This demonstrates that the 
education program was effective in improving knowledge and that there were no adverse effects 
associated with the intervention. Chapter 4 provides a general discussion of the results of both 
studies with reference to the literature review.  
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CHAPTER 1: LITERATURE REVIEW 
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1.1 INTRODUCTION 
Haematopoietic Stem Cell Transplantation (HSCT) is a medical treatment that involves the 
transplantation of blood stem cells. This treatment is more commonly referred to as bone marrow 
transplantation because in the history of this procedure, the stem cells used for transplantation 
were only obtained from the bone marrow (Pavletic & Armitage, 1996). However, today 
haematopoietic stem cells are more commonly collected from peripheral (circulating) blood and 
umbilical cord blood and, as a result, HSCT is now seen to be a more appropriate and inclusive 
term for explaining the procedure.  
 
The purpose of the transplantation is to replace bone marrow stem cells in patients whose 
immune system has been destroyed by lethal levels of chemotherapy and/or radiotherapy that has 
been used to either cure or control the spread of disease (Bone Marrow Transplant Network 
NSW, 2006). The bone marrow, the soft matter found in the hollow bones of the hips, legs and 
arms, produces most of the body’s circulating blood cells, including red and white blood cells 
and platelets. Without HSCT the patient would not be able to endure the toxic doses of 
chemotherapy and/or radiotherapy that is required to kill the cancer or suppress the immune 
system (Bone Marrow Transplant Network NSW, 2006). Healthy stem cells are intravenously 
inserted into the body and they find their way to the bones and become bone marrow. For 
diseases such as lymphoma and leukaemia, HSCT aims to increase the chance of cure. However, 
for illnesses where cure is not possible, such as multiple myeloma, the use of HSCT can help to 
control the spread of disease (Bone Marrow Transplant Network NSW, 2006).  
 
Since its first controversial use in 1968, HSCT has recently become a standard treatment for 
people with cancer (Prieto, Blanch, Atala, Carreras, Rovira, Cirera et al., 2002). For people who 
have a critical blood or immune system disease, HSCT can be a life-saving treatment option 
(Bone Marrow Transplant Network NSW, 2006). Yet traditionally, HSCT was a last resort 
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treatment for incurable diseases used only when all other treatment options had been 
implemented because of the high risk of mortality associated with this procedure (Andrykowski 
& McQuellon, 1999). Advances in tissue typing procedures, improved understanding of the 
immune system, the biological response modifiers, and better supportive care have led to a 
dramatic change in the way HSCT is perceived and used (Lesko, 1994). For instance, it is now 
used earlier in more illnesses with curative intent. HSCT has been used in the treatment of 
leukemia, lymphoma, multiple myeloma, immune system diseases and, less frequently, solid 
tumours (Bone Marrow Transplant Network NSW, 2006; Pavletic & Armitage, 1996). HSCT is 
now being utilised as a “first-line” treatment for some conditions such as multiple myelomas, 
myelodysplastic syndromes, and acquired aplastic anaemia (Andrykowski & McQuellon, 1999). 
Approximately 1000 children and adults undergo HSCT each year in Australia, with about 300 
being performed in New South Wales alone (Bone Marrow Transplant Network NSW, 2006).  
1.2. TYPES OF TRANSPLANTS 
There are two types of transplant: autologous and allogeneic (Bone Marrow Transplant Network 
NSW, 2006). Autologous HSCT, or reinfusion, involves the transplantation of the patient’s own 
stem cells. Allogeneic HSCT involves transplantation of stems cells from a closely matched 
donor (who can be either related or unrelated). A number of factors determine which type of 
transplant a patient will receive. Furthermore, the type of transplant utilised has significant 
implications for prognosis and quality of life following transplantation. 
1.2.1. AUTOLOGOUS TRANSPLANTS 
Autologous transplants are the preferred method of treatment and can be done when the disease 
is responsive to chemotherapy or in remission (Bone Marrow Transplant Network NSW, 2006). 
However, an autologous transplant is not possible if the illness involves the bone marrow, such 
as in Hodgkin’s or non-Hodgkin’s lymphoma, multiple myeloma or acute myeloid leukaemia. 
For autologous transplants, stem cells from the blood or bone marrow of the patient are 
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harvested and frozen prior to the transplant.  The stem cells are then reinfused after high-does 
chemotherapy or radiotherapy. 
1.2.2. ALLOGENEIC TRANSPLANTS 
Allogeneic transplants involve the process of finding a closely matched donor who can be either 
related or unrelated to the patient (Bone Marrow Transplant Network NSW, 2006). Human 
leukocyte antigen (HLA) markers help the body differentiate its own cells from foreign cells 
(e.g. bacteria). People are born with two sets of HLA markers, one from each parent. Since each 
parent has two sets of HLA markers, this means that their children have a one in four chance of 
having the same markers as each other (Bone Marrow Transplant Network NSW, 2006). As a 
result, the patient’s immediate family are the ideal source of donor stem cells, and most 
commonly, the donor will be the patient’s brother or sister. Approximately a third of people will 
have a fully matched donor in their immediate family. When a related donor cannot be secured, 
the transplant doctor will apply to the Australian Bone Marrow Donor Registry to begin a search 
for a donor who has a tissue type that closely matches that of the patient. The process of finding 
an appropriately matched donor can take from weeks to months. Closeness in match between 
donor and patient HLA has a considerable impact on the success of the transplant. Rejection of 
the graft does occur and has serious consequences for the patient’s prognosis. This is why 
allogeneic transplants are riskier than autologous transplants. In Canada, allogeneic transplants 
made up 40% of transplants performed each year (Leger & Nevill, 2004). 
1.3. RISKS ASSOCIATED WITH HSCT 
HSCT is a complex high risk procedure that can involve lengthy and recurring hospitalisation 
and prolonged recovery  (Heinonen, Volin, Zevon, Uutela, Barrick, & Ruutu, 2005). Generally 
the average length of hospital stay for patients having HSCT is five weeks; although this can 
increase when there are complications (Leger & Nevill, 2004). For autologous transplants the 
length of hospital stay is usually shorter with twenty-five days found to be the median length of 
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hospital stay per admission (Moya, Espigado, Parody, Carmona, MÃ¡rquez, & Blas, 2006). In 
the first three months after HSCT about 25% of patients will require at least one readmission 
(Leger & Nevill, 2004). Hospital visits can be necessary for many years following 
transplantation for monitoring patient recovery and blood work. 
 
Short-term side effects of HSCT include nausea, vomiting, diarrhoea, fatigue, mouth and throat 
problems, weight loss, hair loss, and skin reactions (Bone Marrow Transplant Network NSW, 
2006). Some patients, particularly those undergoing allogeneic transplants, may experience long-
term problems with their liver, kidneys, lungs, heart, cataracts and fertility. The risk of 
developing another cancer is also increased with the use of radiation and chemotherapy required 
for HSCT (Bone Marrow Transplant Network NSW, 2006). 
 
Patients who are free of their primary disease two years following the transplantation are referred 
to as long-term survivors (Socie, Veum-Stone, Wingard, Weisdorf, Henslee-Downey, Bredeson 
et al., 1999). Only about 50% of patients with leukaemia who undergo HSCT are expected to 
have long-term survival (Kulkarni, Powles, Treleaven, Riley, Singhal, Horton et al., 2000). 
However, even those who survive HSCT are at risk of other complications, such as graft versus 
host disease (GvHD), bleeding, infections and relapse (Downs, 1994; Kulkarni et al., 2000).  
 
GvHD is the most common complication affecting allogeneic HSCT patients. In GvHD the 
white blood cells from the donor marrow (the graft) attack the patient’s body (the host) because 
the patient’s cells are identified as foreign (Bone Marrow Transplant Network NSW, 2006). 
GvHD is called acute if it occurs within 100 days of HSCT (Leger & Nevill, 2004). If it occurs 
after 100 days, it is referred to as chronic GvHD. Acute GvHD occurs in about 30-50% of 
matched-sibling and 60-80% of unrelated-donor transplant recipients and is characterized by a 
rash, hepatic dysfunction, diarrhea and vomiting (Leger & Nevill, 2004; Weisdorf, 2007). The 
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probability of getting chronic GvHD is 25% (Zittoun, Mandelli, Willemze, de Witte, Labar, 
Resegotti et al., 1995). Chronic GVHD most commonly occurs as a transition from acute 
GVHD, but it can occur also occur without prior acute symptoms in 20-30% of patients. Chronic 
GvHD has been observed in 33% of genetically HLA-identical sibling recipients who survived 
more than 150 days after transplantation, in 49% of recipients of phenotypically HLA matched 
related transplants and in 64% of recipients of HLA-matched unrelated transplants. HLA 
disparity is the major risk factor for GvHD. Other factors that have been found to increase risk of 
GvHD include female donor to male patient, certain HLA alleles and the host environment. 
GvHD can have serious and fatal consequences for patients, depending on the severity of the 
symptoms, which can range from mild to severe. Some of the more common symptoms include 
skin rashes on the hands and feet, problems with the mouth and throat, infections, and 
complications with the liver, gut and lung function. If GvHD occurs it is initially treated with 
high-dose corticosteroid therapy, which has a satisfactory response in 50% to 75% of affected 
patients.  
 
A mortality rate of 80% has been reported for patients with grade III and IV acute GvHD, 
although this figure is likely to be inflated by deaths caused by superimposed infection 
(Przepiorka, Weisdorf, Martin, Klingemann, Beatty, Hows et al., 1995 ). More recently, the 
incidence and severity of, and mortality associated with acute GvHD have significantly 
decreased through the introduction of newer immunosuppressive drug regimens. As a result, the 
most recent survival rates after acute GvHD has been close to 90% (Goerner, Gooley, Flowers, 
Sullivan, Kiem, Sanders et al., 2002). Chronic GvHD is a direct cause of death in about 15% of 
patients.  
 
Compared to Allogeneic HSCT, Autologous HSCT has a lower mortality rate (5-10%) but 
higher rate of relapse of disease (Fefer, 1999; Kulkarni et al., 2000). In a randomised study of 
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patients with Acute Myelogeneous Leukemia in first remission, the risk of relapse was 66% for 
autologous patients and 43% for allogeneic patients (Zittoun et al., 1995). Relapse is thought to 
occur primarily because the conditioning treatments have not been effective in destroying all of 
the remaining host cancer cells (Fefer, 1999). Although relapse can also occur when the 
transplanted autologous cells contain tumour cells (Johns, 1998).  Despite having a lower 
mortality rate, autologous transplants can still have a significantly detrimental effect on quality 
of life due to the physical and emotional consequences of the treatment (Stephens, 2005). 
 
Allogeneic transplants have a greater (around 50%) mortality rate due to the risk of infection and 
GvHD (Kulkarni et al., 2000). For allogeneic transplants, the chance of early non-relapse 
mortality is high (Tichelli, 2007) and there is a greater possibility of death within two years post 
transplantation (Socie et al., 1999). After two years, the chance of survival is higher, although 
the risk of mortality is still greater than in the general population. GvHD can be a ‘double-edged 
sword’ in that because it can reduce the chance of relapse for patients undergoing allogeneic 
HSCT. This is because a graft-versus tumour effect can occur in which the donor’s stem cells 
engraft and attack the cancer cells (Fefer, 1999). Allogeneic patients in first remission from acute 
leukaemia or first chronic phase of Chronic Myeloid Leukemia have a relapse risk ranging from 
20–30% (Aschan, 2006). Risk of relapse increases to 40–60% if transplanted in later remission 
or second chronic phase (Appelbaum, 1997; Horowitz, 1999). Patients not in remission or with 
chemorefractory disease may have a relapse risk exceeding 70% (Aschan, 2006). Long-term 
survival is more likely if patients experience a form of mild acute and/or limited chronic GvHD.  
1.4. LONG-TERM SURVIVAL 
The outcome of HSCT is affected by numerous disease and demographic variables including 
diagnosis, the original disease, the stage of disease, time between diagnosis and transplantation, 
the general health of the patient at the time of the treatment, how well they respond to treatment, 
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type of transplant, HLA matching, source of stem cells, T-cell depletion, age, ethnicity, and the 
sex of donor and recipient (Bone Marrow Transplant Network NSW, 2006; Hoodin, Kalbfleisch, 
Thornton, & Ratanatharathorn, 2004). There has been growth in the number of long-term 
survivors due to the increased use of HSCT and better treatment outcomes (Horowitz, 1999; 
Tichelli, 2007). Today more than 20,000 people have survived for five or more years post-
transplantation. Long term survival is usually accompanied by the decline of the physical side-
effects of treatment, reduced symptoms of disease, a return to pre-illness levels of psychological 
adjustment, and the return to necessary and valued life roles and responsibilities (Andrykowski 
& McQuellon, 1999). Most HSCT patients that are well after five years are no longer taking 
immune suppression and are enjoy a good quality of life (Horowitz, 1999). However, these 
patients remain at risk of late complications. These include infections, cataracts, abnormalities of 
growth and development, thyroid disorders, chronic lung disease, and avascular necrosis. 
Complications are more likely for those patients with chronic GvHD. Furthermore, HSCT 
patients have a greater risk of leukemias, myelodysplasias, and solid tumours than the general 
population. As a result, long term surveillance and awareness of late complications is important 
for these patients (Horowitz, 1999). 
 
Long-term survival and mortality has been investigated in a study involving 6691 patients who 
had remained free of their primary disease for 2 years after an allogeneic transplant (Socie et al., 
1999). As a group, the chance of these patients surviving for another 7 years was high (89%). Of 
these patients, 25% had developed acute GvHD (<100 days) and 43% had developed chronic 
GvHD (100 days +) following transplantation. For 27% of patients, chronic GvHD continued to 
be active 2 years following transplantation. Recurrent leukaemia and chronic GvHD were 
identified as the two main causes of late death in HSCT recipients (Socie et al., 1999). Chronic 
GvHD resulted in late death either directly through complication, such as bronchiloitis 
obliterans, or indirectly by increasing susceptibility to infections due to immunodeficiency.  
  12
 
A study which examined treatment-related mortality in 1000 consecutive patients who had 
undergone autologous transplantation for leukemia, non-Hodgkin’s lymphoma, Hodgkin’s 
disease, multiple myeloma, sarcoma, ovarian cancer and breast cancer found 5.9% of patients 
died within 100 days of treatment (Weaver, Schwartzberg, Hainsworth, Greco, Li, Buckner et 
al., 1997). Approximately 3.4% died because of treatment-related side effects, half due to 
infection and half to regimen-related toxicity. Progression of the disease accounted for the other 
2.5% of deaths. The patients who died were more likely to have advanced and more refractory 
types of disease. Age was also shown to be a predictor of higher mortality (Weaver et al., 1997). 
 
In a study examining 27 patients with high risk or relapsing leukaemia, 27 (15%) patients died 
from relapse, and nine (33%) from transplantation-related complications. Fourteen patients 
(52%) were still alive and in ongoing complete clinical remission when the study was published 
(Reske, Bunjes, Buchmann, Seitz, Glatting, Neumaier et al., 2001). A more recent study reported 
a survival rate of 43% for 21 patients with high-risk acute myeloid leukaemia, myelodysplastic 
syndrome or advanced myelodysplastic syndrome at follow up of 23–60 months. The treatment-
related mortality was 28.6% and an equal number of patients died of relapsing disease within 
30–385 days after transplantation (Koenecke, Hofmann, Bolte, Gielow, Dammann, Stadler et al., 
2008).  
1.5. PSYCHOSOCIAL SEQUELAE AND HSCT 
Due to the arduous nature of HSCT, patients and families are often put under considerable stress. 
Some of the psychological sequelae that patients undergoing HSCT experience are psychological 
distress, anxiety over loss of control, physical complaints, sexual dysfunction, problems with 
social relationships, occupational disability and financial consequences (Baker, 1994). People 
who undergo HSCT can be affected physically, psychologically, socially and spiritually due to 
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the high level of trauma associated with the procedure (Krasuska, Dmoszynska, Daniluk, & 
Stanislawek, 2002). Poor social support, a history or current symptoms of depression or 
substance abuse, and rigid or inflexible coping styles are factors that have been identified as 
being associated with poor coping with the HSCT process (Andrykowski & McQuellon, 1999). 
A qualitative study, using multidimensional scaling and hierarchical cluster analyses to rank 
primary stress clusters, found HSCT patients were most to least distressed by: change of life and 
long-lasting treatment, side-effects, treatment outcome and health status, family-related distress, 
death and depressive thoughts, other concerns, negative social support and lack of information 
and medical staff (Heinonen et al., 2005). It has been suggested that patients undergoing HSCT 
benefit from being informed about the possible psychosocial effects of treatment as it can help 
patients with decision-making and provide realistic ideas about what to expect after HSCT 
(Broers, Kaptein, Le Cessie, Fibbe, & Hengeveld, 2000).  
1.5.1. PSYCHOSOCIAL SEQUELAE OVER DIFFERENT STAGES OF HSCT 
Researchers have identified physical and psychological factors that are likely to be present 
during the major stages of the HSCT process (Andrykowski & McQuellon, 1999; Brown & 
Kelly, 1976; Haberman, 1988). Although the number of stages discussed in the literature varies, 
there appears to be six major stages involved in the HSCT process including: (1) making the 
decision to undergo HSCT, (2) preadmission, (3) the conditioning regimen, (4) 
immunosuppression and isolation, (5) transplantation and engraftment and (6) hospital discharge 
and follow-up (Brown & Kelly, 1976; Haberman, 1988).  
 
Because the chance of disease cure or long-term disease-free survival is uncertain, the decision 
to undergo HSCT is a stressful stage for most patients and their families (Andrykowski & 
McQuellon, 1999). Common issues that may be present in the decision making stage include: 
facing the chance of death, coping with the uncertainty of the treatment outcome, dealing with 
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financial and insurance restrictions and consenting to treatment (Andrykowski & McQuellon, 
1999). Patients need to prepare themselves for a range of highly distressing short-term and long-
term side effects even in the ‘best case’ scenario. Patients may even be faced with an earlier 
death if they undergo HSCT than they would have if they had continued with other more 
conventional treatments or even palliative care (Andrykowski & McQuellon, 1999). However, 
even though the treatment outcome is uncertain, patients appear to be prepared to endure 
considerable toxicity and face greater risk of mortality for an increased chance of survival. 
Patients are likely to experience a range of emotions during this time including shock, anger, 
anxiety, disbelief and confusion (Haberman, 1988). There is a paucity of research about the 
process prospective HSCT patients go through in deciding whether to undergo HSCT. 
Andrykowski and McQuellon (1999) have argued that the patient may already be 
psychologically committed to HSCT once the referring physician has suggested it to them as a 
treatment option; particularly when it is presented as a last resort. This may mean that patients 
make the decision to undergo HSCT prior to receiving information about the risks and benefits 
from the transplant centre. However, for many patients HSCT will be the only viable treatment 
option. 
 
During the second stage, preadmission to hospital, patients often experience anxiety in 
anticipation of the transplantation (Haberman, 1988; Lesko, 1994). Some authors have argued 
that anxiety is exacerbated by a lack of knowledge about the treatment (Lesko, 1994). 
Surprisingly, the pre-treatment stage of HSCT may provoke higher levels of distress in patients 
than the actual day of transplant, possibly due to a lack of knowledge about the treatment process 
and the uncertainty associated with treatment (Brown & Kelly, 1976). This finding is not limited 
to HSCT patients. In breast cancer, for example, the time between diagnosis and treatment has 
been shown to be the most distressing stage for patients (Moyer & Salovey, 1996). Feelings of 
uncertainty about what to expect from treatment is seen to be an important factor contributing to 
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patients’ anxiety and distress (McQuellon, Wells, Hoffman, Craven, Russell, Cruz et al., 1998). 
Patients need to organise their personal affairs and say goodbye to family and friends so that they 
can focus on coping with the treatment ahead. Some patients try to prepare family and friends for 
the possibility of their death and as a result may decide to make funeral arrangements and 
organise wills (Haberman, 1988). Patients may want to deal with these matters while they are 
capable of doing so and to make sure that their loved ones are not burdened by these 
arrangements at a later time. Families may need to relocate for treatment and make arrangements 
for leave of absence from work or educational commitments. Patients can also be required to 
wait for the results of medical tests and for a hospital bed to become available (Haberman, 
1988). Prior to being admitted to hospital, HSCT patients undergo what is called ‘the work up’, 
which involves routine medical tests to ascertain that the patient’s body will be well enough to 
withstand the physical demands of HSCT (Bone Marrow Transplant Network NSW, 2006). The 
work up may involve investigations of the heart, the kidney, lung function, sinus infection, blood 
tests, assessment of dental health and nutrition, and discussions about options for preserving the 
possibility of having children after HSCT in younger patients. Patients may experience 
frustration, anger and anxiety during this stage because it can feel as if they are stuck in limbo 
due to the protracted waiting period (Haberman, 1988).  A retrospective study found that 28% of 
patients described symptoms during the pre-treatment stage that would have met criteria for a 
major depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders 
III (DSM-III) (Jenkins, Linnington, & Whittaker, 1991). The same authors conducted a 
prospective study with patients about to undergo HSCT and found that 16% met criteria for 
major depressive disorder (Jenkins, Lester, Alexander, & Whittaker, 1994). 
The conditioning regimen is the third major stage of the HSCT process (Haberman, 1988). In the 
days leading up to the transplant, patients undergo a conditioning or preparative therapy over 1 
to 10 days (Andrykowski & McQuellon, 1999; Bone Marrow Transplant Network NSW, 2006). 
Usually this phase involves extremely high doses of chemotherapy drugs. Occasionally, a 
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conditioning regimen called Total Body Irradiation Therapy  is also used to suppress the 
recipient’s immune system for acceptance of the graft and to eradicate the recipient’s underlying 
disease and bone marrow (Thomas & Storb, 1999). Thus the aim of this stage of the treatment is 
to destroy the cancer cells, to a greater extent than is normally possible, and/or to suppress the 
immune system so that the donors stem cells are not rejected (Bone Marrow Transplant Network 
NSW, 2006). Patients frequently experience symptoms of nausea and vomiting, hair loss, 
diarrhoea, fatigue, and painful mouth ulceration (mucositis) which continue even after the 
treatment has been completed. Total body irradiation has been recognised as a significant cause 
of distress during this stage (Brown & Kelly, 1976). Patients may have doubts about the need for 
such toxic levels of radiation. The symptoms associated with the conditioning regimen may 
bring to the forefront of patients’ minds doubts and fears which they have previously been able 
to manage.  
 
The fourth major stage involves immunosuppression and germ-free isolation (Haberman, 1988). 
Patients are often severely immunoincompetent for weeks or months; and this period is longer 
for allogeneic transplants (Thomas & Storb, 1999). As a result, the patient is at extremely high 
risk of infection and needs to be kept isolated from sources of contamination (Bone Marrow 
Transplant Network NSW, 2006). Otherwise, it is possible for patients to become inundated by a 
range of infections that are rare in healthy people. After the conditioning phase, patients are left 
with no option but to have the transplantation since without it they will certainly die. The period 
of isolation, when patients are at risk of infection, has been identified as a stage in which HSCT 
patients may be more psychologically vulnerable. This appears to be more likely for individuals 
who are inclined to be active (Brown & Kelly, 1976). It has been suggested that minimal 
physical contact with others and intensive nursing care are extremely detrimental to patients’ 
psychological functioning. Because young children have an increased risk of infection they are 
typically prevented from entering the isolated unit. This can be an additional stressor for HSCT 
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patients who have young children as both the parent and children must endure the distress of 
separation. In a sample of leukaemia patients, 41% met criteria for a mental disorder during the 
period of isolation (Sasaki, Akaho, Sakamaki, Akiyama, Yoshino, Hagiya et al., 2000). The most 
frequent diagnosis given was adjustment disorder with anxiety and/or depression.  
 
The actual transplantation and the period of waiting for the engraftment to occur is the fifth 
major stage of treatment (Haberman, 1988). The day of HSCT is often experienced as anti-
climatic because the infusion of the stem cells is more often than not a short and straightforward 
procedure. However, the day of transplantation may have emotional significance similar to a new 
beginning for some patients and families (Lesko, 1994). A period of waiting then occurs after 
transplantation, when the patient is monitored for symptoms and signs that the graft has been 
successful and the immune system has returned to normal functioning. This occurs until the 
patient’s white blood cell count rises above 0.5, indicating that the bone marrow is producing 
new cells (Bone Marrow Transplant Network NSW, 2006). This waiting period can produce high 
levels of distress due to feelings of vulnerability and loss of control (Andrykowski & 
McQuellon, 1999). The threat of death or serious side effects is often more present at this time 
(Haberman, 1988). Patients often experience the effects of prolonged and confined 
hospitalisation including boredom, regimentation, loss of control and diminished sense of 
personal identity (Andrykowski & McQuellon, 1999). 
The final stage of transplantation involves discharge from hospital and prolonged recovery as an 
outpatient (Andrykowski & McQuellon, 1999; Haberman, 1988). Some anxiety about separating 
from the care of hospital staff may be present at this time. Patients may be worried about 
whether they and their family will be able to cope with emergencies or serious side effects. In 
addition, patients may develop close bonds with particular nursing staff. Studies have indicated 
that some HSCT patients identify particular nurses as key support persons rather than their 
spouses or partners. Molassiotis, van den Akker, and Boughton (1997) looked at perceptions of 
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social support in long-term survivors of HSCT. Twenty-three percent of HSCT patients named at 
least one nurse who was a primary source of support for them; suggesting the important role that 
nurses can have in patient care and recovery as well as in relation to quality of life. Once patients 
return home, readjusting to normal life can be difficult due to ongoing concerns and risks about 
health (Haberman, 1988). Patients are still likely to feel physically compromised and easily 
exhausted (Andrykowski & McQuellon, 1999). Patients are also required to wear a protective 
mask in public which can be a source of embarrassment and difference (Haberman, 1988). 
Patient’s expectations of life after HSCT can have implications for how well they adapt to this 
phase (Andrykowski & McQuellon, 1999). For instance, if patients expect that their life will 
return to normal following transplantation, then it will be much harder for them to adjust; at least 
in the short term. The threat of marrow failure, graft rejection, chronic GvHD, relapse and death 
continue to be present at this stage and therefore anxiety and depression may occur in response 
to fear of these negative outcomes (Haberman, 1988). A subgroup of about 25% of transplant 
survivors have been found to have moderate to severe psychological symptoms following HSCT 
(Hjermstad & Kaasa, 1995). The distressing reality for many survivors, particularly those who 
have had allogeneic transplants, is that they are never likely to be “non-patients” again because 
of the continuing need for monitoring and the possibility of late complications (Tichelli, 2007). 
 
1.5.2. PSYCHOSOCIAL DISTRESS AND RATES OF DISORDER  
Rates of psychopathology in oncology have been found to vary depending on type of cancer, 
prognosis and burden of illness. Generally, a third of cancer patients are likely to experience 
clinical levels of distress (Zabora, BrintzenhofeSzoc, Curbow, Hooker, & Piantadosi, 2001).  
Lung cancer patients (43.4%) were found to have higher rates of distress than patients with 
gynaecological cancers (29.6%) (Zabora et al., 2001). HSCT patients have been shown to have 
even higher rates of clinical distress than other cancer patients (Trask, Paterson, Riba, Brines, 
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Griffith, Parker et al., 2002). This finding is not surprising considering the fact that HSCT has 
much higher risk of mortality and more stressful side effects (Andrykowski & McQuellon, 1999; 
Langer, Abrams, & Syrjala, 2003; Lesko, 1994). Fifty percent of patients undergoing HSCT are 
likely to experience clinical levels of distress prior to receiving information about their treatment 
(Trask et al., 2002). This rate has also been found at other time points such as immediately 
following HSCT and follow-up (Neitzert, Ritvo, Dancey, Weiser, Murray, & Avery, 1998). For 
instance, Leigh, Wilson, Burns and Clark (1995) found rates of clinical psychopathology in 54% 
of patients before and after treatment with HSCT. Six to nine months later, patients still rated 
highly on psychological distress. Fife et al. (2000) investigated emotional distress after admission 
to hospital and before HSCT infusion. These authors found that patients were most vulnerable to 
psychosocial distress during hospitalisation prior to HSCT. Three months and 1 year after 
transplantation were the time points that were associated with the least distress. Similarly, Broers 
et al (2000) found higher levels of anxiety prior to treatment compared to post HSCT. Degree of 
emotional distress at baseline, personal control, cognitive response, and symptomatology 
(physical and emotional symptoms) were the factors most likely to affect patients’ emotional 
distress and adaptation.  
 
One study compared the National Comprehensive Cancer Network Distress Thermometer (DT) 
with a cut-off score of 5, with the Anxiety and Depression Scales of the Hospital Anxiety and 
Depression Scale (HADS) in a sample of 50 candidates for HSCT (Trask et al., 2002). These 
researchers found that 50% of the patients met the cutoff of 5 on the DT, 51% of patients met 
cutoff of 8 for the HADS anxiety subscale, and less than 20% (the authors did not specify how 
much less) met the cut-off of 8 for the depression subscale. There was no investigation of the 
concordance of the measures in this study. Keogh and colleagues (1998) conducted a prospective 
repeated measures study pre and post HSCT in a sample of 28 patients. They found moderate to 
high levels of anxiety and depression in 61% and 14% of patients respectively pre-treatment 
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using the HADS. Three months later, rates of clinical anxiety had reduced to 20%. However, 
clinically significant cases of depression had increased to 40%. At 12 month follow-up 33% and 
14% remained as clinically significant cases of anxiety and depression. Jenks Kettmann & 
Altmaier (2008) found higher rates of clinically significant depression, with 29.1% of patients 
meeting the cut-off point before HSCT and 27.6% one year post-HSCT. These studies support 
the view that a significant proportion of HSCT patients experience elevated levels of distress 
throughout the treatment process. 
 
Although not all distressed patients fulfil criteria for some form of psychiatric diagnosis, some 
patients do. One study of patients admitted to hospital for HSCT investigated rates of psychiatric 
disorders based on clinical interviews (Prieto et al., 2002). Using the Diagnostic and Statistical 
Manual of Mental Disorders IV (DSM-IV), the prevalence of a mood disorder was 14.1%. 
However, the authors found overall psychiatric disorder prevalence to be 44.1%. Another study 
reported 28% of patients who had undergone HSCT described symptoms from pre-treatment that 
would have met criteria for clinical depression (Jenkins et al., 1991). These results were 
confirmed in a prospective study that found that 16% of patients met criteria for major depressive 
disorder pre-HSCT (Jenkins et al., 1994). In addition to elevated levels of distress, severe 
symptoms sufficient to warrant diagnosis are more common than in the general population. The 
poor prognosis, demanding treatment, and wealth of physical complaints likely contribute to 
these elevated rates of psychological disorder and distress.  
1.5.3. EFFECTS OF DISTRESS AND DISORDER IN HSCT PATIENTS  
Examining the rates of distress and disorder in HSCT is important because apart from the 
obvious burden of psychological distress, high levels of distress have been associated with 
adverse outcomes for quality of life, physical condition, adaptation to illness and adherence to 
care regimens and survival (Colon, Callies, Popkin, & McGlave, 1991; Goetzmann, Klaghofer, 
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Wagner-Huber, Halter, Boehler, Muellhaupt et al., 2007; Hann, Jacobson, Martin, Kronish, 
Azzarello, & Fields, 1997; Sutherland, Fyles, Adams, Hao, Lipton, Minden et al., 1997).  
 
There have been few methodologically sound investigations of the effect of psychological 
variables on survival in HSCT (Hoodin et al., 2004). Nevertheless, the limited research in this 
area suggests that depression can have a negative effect on survival in HSCT patients. 
Specifically, negative emotional profiles before HSCT are associated with worse survival in the 
long term whereas optimism about the treatment appears to positively affect survival in the short 
term (Hoodin, Uberti, Lynch, Steele, & Ratanatharathorn, 2006). Major depression has been 
found to be associated with higher risk of death in patients who have been treated with HSCT at 
1 and 3 years post transplant (Prieto, Atala, Blanch, Carreras, Rovira, Cirera et al., 2005). 
However, this association was not found for patients 5 years after HSCT. The authors concluded 
that these findings emphasise the need for efficient and thorough diagnosis and treatment of 
major depression in patients undergoing HSCT. Hoodin and colleagues (2004) also found that 
patients with lower levels of depression prior to undergoing HSCT survived longer than those 
with higher levels of depression. However, no differences in survival were found for patients 
with or without anxiety. 
 
1.5.4. DIFFERENTIATING PATIENTS SUSCEPTIBLE TO DISTRESS 
Although there are high rates of distress, not all patients facing these grave outcomes experience 
clinical levels of psychopathology. It is of interest to understand what factors might differentiate 
those who show clinical levels of distress from those who do not. Despite there being little 
research that helps to identify what factors differ in patients undergoing HSCT, there are theories 
supported by evidence in other areas that may be relevant.  
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Self-Regulation Theory (SRT) asserts that individuals use information from concrete and 
abstract sources to construct schematic representations of illness and health-threats (Leventhal, 
Meyer, & Nerenz, 1980). According to SRT a coping response will be activated if information is 
perceived as threatening. While a health professional may provide advice, how patients respond 
to that advice is determined by their illness schema. SRT is a dynamic process that is also 
influenced by lived experience of the illness (Leventhal, Nerenz, & Steele, 1984). Patients’ 
knowledge of others’ experiences may affect their illness representations. For example, if a 
HSCT patient has a friend who had a good recovery from transplantation they may be more 
likely to attribute less danger to the treatment. Thus, schemas are constantly modified and 
updated based on new information. Illness representations have been found to be 
multidimensional and apply to a range of illnesses (Weinman, Petrie, Moss-Morris, & Horne, 
1996). Although, aspects such as the structure and levels of the representations may vary across 
illnesses (Heijmans & De Ridder, 1998).  
 
Based on SRT, the development of the Illness Perception Questionnaire-Revised enabled 
measurement of the constructs related to SRT (Hagger & Orbell, 2005). Petrie, Jago and Devcich 
(2007) define illness perceptions as the beliefs or cognitive structures that patients use to 
describe their illness. Illness perceptions can include patients’ beliefs about illness identity 
(symptoms attributed to the illness), cause of illness, personal consequences, personal control 
and treatment control. Patients with the same illness can have very different illness perceptions 
depending on the information they have and their experiences (Petrie et al., 2007).  
Illness representations have been found to be relevant to emotional adjustment and recovery in a 
range of illnesses including gastroenteritis, MS, Huntington's disease, rheumatoid arthritis and 
diabetes (Helder, Kaptein, van Kempen, Weinman, van Houwelingen, & Roos, 2002; Parry, 
Corbett, James, Barton, & Welfare, 2003; Skinner, Hampson, & Fife-Schaw, 2002; Vaughan, 
Morrison, & Miller, 2003). Illness perceptions have also been found to be significantly 
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correlated with quality of life in patients diagnosed with head and neck cancer (Scharloo, 
Baatenburg de Jong, Langeveld, van Velzen-Verkaik, Doorn-op den Akker, & Kaptein, 2005). A 
new line of research has started to look at the effectiveness of changing illness perceptions when 
they are detrimental to behaviour and treatment responsiveness. One study on patients having 
myocardial infarction found reduced disability and faster return to work following an 
intervention to change patient illness beliefs (Petrie, Cameron, Ellis, Buick, & Weinman, 2002).  
 
Tham and Gibbon (1996) conducted an exploratory qualitative study of the perceptions of 
patients who had undergone HSCT. Using unstructured interviews, these authors found five 
broad categories emerged as important: mortality and death, luck, protective isolation (‘prison’), 
relationships and physical effects. This study was based on a small sample of six patients and 
focus upon broad concerns rather than illness perceptions. Nevertheless, it highlighted patients’ 
greater concerns for mortality and death over physical effects following transplantation. Another 
study investigated health beliefs and coping styles in patients scheduled to have autologous 
HSCT (Frick, Fegg, Tyroller, Fischer, & Bumeder, 2006). They found that patients were most 
likely to attribute causal attribution to chance. A causal attribution of self-blame was associated 
with a depressive coping style and a relation was found between fate or destiny causal 
attributions and a religious coping style. Most patients in this study had a control style that was 
externally oriented. That is, they were more likely to attribute control to their physicians and 
nurses. To date there have been no studies specifically examining the illness perceptions of 
HSCT patients. 
1.6. PSYCHOSOCIAL IMPACT ON CARERS AND FAMILY 
Due to the long-term care required by the HSCT patient, support from family and carers is 
critical to their management (Franco, Warren, Menke, Craft, Cushing, Gould et al., 1996). The 
existing literature highlights the crucial function of the family in providing optimum adaptation 
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and recovery from HSCT (Boyle, Blodgett, Gnesdiloff, White, Bamford, Sheridan et al., 2000). 
In the field of oncology generally, perception of social support has been acknowledged as having 
an important influence on coping, health behaviours, illness outcomes, and survival (Boyle et al., 
2000). Families are involved in both the acute and long-term care of the patient, once they have 
been discharged from hospital. There has been limited research, however, on the support needs 
and experiences of HSCT carers and families (Boyle et al., 2000; Foxall & Gaston-Johansson, 
1996). Understanding the experience of carers in HSCT is likely to have important implications 
for the long-term functioning and quality of life of HSCT carers and patients (Boyle et al., 2000); 
allowing for the development of effective and timely interventions that facilitate coping and 
adaptation to the HSCT process (Foxall & Gaston-Johansson, 1996).  
1.7. CAREGIVER BURDEN 
While the caregiving experience has been looked at to a small extent in the cancer literature, 
these studies have been largely descriptive (Langer et al., 2003). Caregiver burden has primarily 
been examined for carers of patients with neurological disorders (e.g. stroke, Alzheimer’s, and 
traumatic brain injury). The term ‘caregiver burden’ has been used to describe a range of 
difficulties experienced by carers, such as physical, psychological, emotional, social and 
financial problems (Given, Given, Stommel, Collins, King, & Franklin, 1992). In essence, 
caregiver burden conceptualises the caregiver’s response to caring responsibilities that may have 
negative consequences for their physical and psychological health (Boyle et al., 2000). 
A longitudinal study of family caregiver burden in carers of advanced breast cancer patients 
found carers had similar levels of depression but significantly greater anxiety compared to 
patients at the start of the palliative period (Grunfeld, Coyle, Whelan, Clinch, Reyno, Earle et al., 
2004). Burden was the biggest predictor of caregiver anxiety and depressive symptomatology. 
Decline in patients’ functional status was associated with increases in caregivers’ depressive 
symptoms and burden. Another study investigating the effects of caregiving on spouses of 
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advanced cancer patients demonstrated that they have a high-risk of developing depression 
(Braun, Mikulincer, Rydall, Walsh, & Rodin, 2007). Higher rates of depression were 
demonstrated for spousal caregivers compared to patients (38.9% vs. 23%). Subjective 
caregiving burden, caregiver's anxious attachment, caregiver's avoidant attachment, and 
caregiver's marital satisfaction were found to make significant contributions to carer depression. 
Therefore, caregiver burden is an important issue in cancer settings.  
1.7.1. CAREGIVER BURDEN IN HSCT 
A few studies have examined caregiver burden in HSCT. Caregivers of HSCT patients 
experience substantial burden and responsibility caring for these extremely ill patients (Foxall & 
Gaston-Johansson, 1996). Stressors that are thought to impact on caregiver burden in HSCT 
include unexpected and rapid changes in the patient’s prognosis, numerous invasive medical 
procedures, recurring infections, risk of death, prolonged hospitalisation, separation from other 
family members, and disruptions to home life and work commitments (Foxall & Gaston-
Johansson, 1996; Lesko, 1994). The limited research in this area suggests that families often feel 
unprepared for the intense and continual demands of the transplant process (Boyle et al., 2000). 
Misunderstanding about the ongoing care required by HSCT patients can result in families 
feeling ill-equipped to continue in the caregiving role. Spouses and partners are often the primary 
carers and as such may be required to juggle the care demands of the patient, other family 
members (e.g. children, elderly parents), career and other responsibilities. In families in which 
the patient was a primary bread-winner prior to becoming sick, role changes are often required, 
adding further burden to family members. Furthermore, patients and families often have to travel 
long distances for treatment which may require families or carers to obtain temporary housing 
near the transplant centre (Blume & Amylon, 1999).   
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Most of the information on carer burden in HSCT patients is based upon qualitative designs. 
However, Foxall and Gaston-Johansson (1996) conducted a descriptive correlational study with 
repeated measures to investigate caregiver burden in 24 family caregivers one week prior to 
patient admission and five and 20 days after transplantation. These authors consider caregiver 
burden to be a multidimensional concept made up of objective and subjective burden. Objective 
burden refers to tangible events, financial difficulties, personal activity restrictions, family 
disruptions, and family tension. Subjective burden is defined as feelings, attitudes and affects 
experienced by the caregiver (Foxall & Gaston-Johansson, 1996). For carers of HSCT patients, 
objective burden was found to be a larger issue than subjective burden across all of the stages 
measured. Fatigue, disruption to everyday life and financial strain were the most frequently 
endorsed items of objective burden. Greater burden post HSCT was related to poorer health 
outcomes (including distress) for carers in the short-term.  
 
Krususka et al. (2002) contend that family and carers of HSCT patients experience significant 
interpersonal and personal distress throughout the transplantation process. Interestingly, Foxall 
and Gaston-Johansson (1996) found that caregivers as well as patients experienced higher levels 
of anxiety in the lead up to HSCT compared to days five or 20 post HSCT. One week prior to 
HSCT, caregivers were found to have moderate levels of anxiety on the State Trait Anxiety 
Inventory (STAI). Yet there was no indication that the different stages of HSCT were likely to 
lead to depression in caregivers in this study.  
 
Langer et al. (2003) examined affect and marital satisfaction in patients undergoing HSCT and 
their carers at three time points: prior to transplantation, six months post transplantation, and one 
year post transplantation. Compared to non-medical controls, caregivers reported higher levels of 
anxiety and depression. There was also a significant decline in relationship satisfaction for 
couples at both six months and one year following HSCT. Although couples were matched in 
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relationship satisfaction prior to HSCT, caregivers appeared to feel increasingly dissatisfied 
compared to their partners. Interestingly, this mismatch in relationship satisfaction was not 
related to patient physical or psychological characteristics but was related to the gender of the 
caregiver. Female caregivers were more likely to become dissatisfied with their relationship over 
the course of treatment than male caregivers were.  
 
As has been described, HSCT is a potentially dangerous and highly demanding procedure. The 
patients for whom HSCT is the treatment of choice usually have serious conditions that without 
transplantation are likely to be life-limiting. This reality needs to be balanced against the risks of 
the procedure itself, which can result in premature death in a small but significant proportion of 
patients. Therefore, it is essential that patients are properly informed about the pros and cons of 
treatment prior to deciding whether or not to have the procedure. 
1.8. INFORMED CONSENT 
As the conditions that are treated with HSCT were previously associated with extremely high 
rates of mortality, the advent of HSCT has given hope to a group of patients for whom there 
were previously no effective treatment options. However, as has been described, the procedure is 
not without a range of risks and possible complications that patients and their families need to 
take into account when deciding about treatment. The values which patients place on both the 
possible positive and negative outcomes of treatment are likely to have an impact on decision 
making (Gattelari, Butow, & Tattersall, 2001). Current models of medical care are increasingly 
embracing the concept of shared-decision making, where patients are becoming more involved in 
their care than has previously been the case and are thereby taking more responsibility for the 
health and medical treatment decisions that affect them. 
1.8.1 MODELS OF INFORMED CONSENT 
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In the history of medical care prior to the 1980s, patients invariably took a subsidiary role in 
terms of decision making about their medical treatment and doctors were seen to be omnipotent 
and beyond reproach (Charles, Gafni, & Whelan, 1999). This type of patient-doctor relationship 
has been characterised as the paternalism model, otherwise known as the physician as agent 
model, in which decisional authority is vested solely in the hands of the doctor who is viewed by 
the patient as the expert advisor (Gattelari et al., 2001). The major assumptions of this model are 
that there is a gold standard treatment for every illness, that all doctors are up to date with the 
latest treatment practises, that doctors apply this information about best treatments without fail, 
that doctors are in the best position to weigh up trade-offs between different treatments and make 
the best decision, and that doctors have a genuine investment in every treatment decision due to 
their professional concern for the rights, welfare and personal interests of patients (Charles et al., 
1999). In the paternalism model, while the patients’ values may be elicited and considered, the 
doctor is seen to have the final say over the decision making process. One of the primary dangers 
of this model is that the patient’s autonomy may be undermined (O'Conner, 1989). This is 
especially a concern when the information given by the doctor, or to doctor by the patient, is 
biased or incomplete or when the choice between two treatment options is finely balanced. The 
paternalism model also places the doctor in a position of overall and almost exclusive 
responsibility for any error in the decision-making process resulting in a wrong decision being 
made concerning treatment. 
 
Beginning in the 1980s, there has been a growing dissatisfaction with this imbalanced 
relationship between doctors and patients (Charles et al., 1999). Improvement in patient 
education, access to information, medical negligence/liability litigation and changing societal 
ideas about the role of doctors, has contributed to the emerging attitude that the medical 
profession should be held responsible for its conduct and decisions (Gattelari et al., 2001). 
Furthermore, it became apparent that there were a number of illnesses that did not have clear 
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treatment options,  making treatment decisions more complex due to the reality of a trade-off 
between risks and benefits (Charles et al., 1999). These changes have had implications for the 
law and policy-making. In the United States, the Patient Bill of Rights states that patients must 
be given written information prior to undergoing a medical procedure (Climent, 1999). Although 
there is no law to this effect in Australia, landmark cases have highlighted the need for doctors to 
provide patients with adequate information about the adverse effects of medical treatment 
(Gattelari et al., 2001).  
 
These changes have led to a change in the dominant model of medical decision-making. The 
informed choice model, or patient-led decision making, was developed in response to the 
rejection of the paternalistic model and is at the opposite of the spectrum in terms of physician 
and patient involvement in medical decisions (Charles et al., 1999). In the informed choice 
model, the knowledge and expertise of the doctor is acknowledged but the patient is seen to be 
capable of coming to a thoroughly informed decision (Gattelari et al., 2001). Like the 
paternalistic model, the informed choice model is largely one-way in terms of information 
exchange (Charles et al., 1999). However, in this model the patient takes the responsibility for 
accessing information from the physician. The informed choice model also assumes that patients 
have the skills necessary to obtain information that they need from the doctor and other sources, 
make sense of the information about treatment alternatives, express their preferences and values 
and are able to formulate all of these factors in order to come to a well thought out decision. In 
the informed choice model, the doctor’s role is to openly disclose information but they are not 
expected to advocate for one treatment choice or another. Research examining patient 
preferences for participation in decision making indicates that although the majority of patients 
want to be involved in medical decisions, they also want their physician to help them in deciding 
which approach to take with their treatment (Freedman, 2002). It has been found that patients 
sometimes misunderstand information about their treatment, such as the likelihood that treatment 
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would cure their disease. This was also shown to be predicted by patient denial and anxiety and 
doctors’ ability to communicate effectively (Gattelari, Butow, Tattersall, Dunn, & MacLeod, 
1999; Ley, Bradshaw, & Kincey, 1973).  
 
The literature shows that the majority of patients and physicians no longer support the extreme 
positions advocated by the paternalistic or informed choice models. Rather, most authors now 
support a shared-decision making paradigm which is seen to be a compromise between 
paternalism and informed choice (Makoul & Clayman, 2006). In the shared decision making 
model, doctors and patients are viewed as equal in status and are both expected to share 
responsibility, information and preferences with the aim of arriving at a negotiated and mutually 
acceptable treatment decision (Gattelari et al., 2001). Charles, Gafni and Whelan (1999) have 
outlined four characteristics that they see as essential for shared decision making: (1) both the 
physician and the patient are involved in the decision making process, (2) both share information 
with each other, (3) both take steps to participate in the process by sharing preferences, and (4) 
the treatment decision is made jointly and both agree on the best treatment to perform.  
1.8.2. RESEARCH ON INFORMED CONSENT  
Involving patients in the decision making process is generally looked upon favourably by both 
physicians and patients (O'Conner, Llewellyn-Thomas, Sawka, Pinfold, To, & Harrison, 1997). 
Overall, the increased importance placed on informing and educating patients has evolved due to 
a number of factors including the focus on shared decision making, technological advances in 
health care and the resulting complex treatment regimens, more rigorous guidelines for consent 
procedures, litigation, reimbursement policies, and consumer demands (Fernsler & Cannon, 
1991; Gurrud, Wood, & Stainsby, 2001). When the risks of a particular treatment are high and 
the outcomes uncertain, patient-involved decision making is seen to be especially important 
(Gattelari et al., 2001). The literature suggests that most cancer patients want detailed 
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information about diagnosis, treatment, side effects, symptoms and self-care needs (Hagerty, 
Butow, Ellis, Lobb, Pendlebury, Leighl et al., 2004; Treacy & Mayer, 2000). Cancer patients 
have reported feeling dissatisfied with the quality and quantity of information that they have 
been given about their illness and treatment. Indeed, in a study conducted by Blanchard, 
Labrecque, Ruckdeschel and Blanchard (1988) adult patients with cancer reported that they 
preferred to receive all the information about their disease and treatment regardless of whether it 
was good or bad. Perceived lack of information about treatment and related risks has been found 
to be associated with increased anxiety, uncertainty, dissatisfaction, distress and poor treatment 
decisions in patients with cancer (Fallowfield, Ford, & Lewis, 1995; Gamble, 1998).  
 
Information-seeking has been shown to be a coping strategy for some patients with cancer which 
helps them to gain a sense of control and mastery over their illness (Derdiarian, 1987; Treacy & 
Mayer, 2000). Lazarus (1966) has suggested that seeking information helps to alleviate fear and 
concerns of harm in potentially dangerous situations. However, shared decision-making is not 
without its own consequences in situations where prognostic information may be considerably 
uncertain and frightening, since informed decision-making requires patients to be knowledgeable 
about their illness and the treatment that they undergo. This is a particular issue in HSCT 
because the treatment is very complicated and the prognosis is worse than for many cancers and 
other treatment procedures. When HSCT was largely utilised as a treatment of last resort, the 
decision to undergo transplantation was easier because candidates had very few alternative 
options. Now that it is being used as a “first line” treatment for some conditions, such as breast 
cancer, the decision to undergo HSCT is likely to be more difficult and distressing (Andrykowski 
& McQuellon, 1999; Hann et al., 1997). In a sample of HSCT patients who attended an 
appointment where a doctor discussed the risks and benefits of treatment, patients had higher 
levels of psychological distress 48 hours later (Dermatis & Lesko, 1991). Whether it was the 
information, the imminent need for the procedure or the natural course of adjustment that was 
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responsible for the increase in distress is unknown. Nonetheless, elevated levels of distress can 
affect how well patients understand the information provided. However, in the area of oncology 
generally, educational programmes have been encouraged so that patients have the opportunity 
to gain a good understanding of their illness and hence can be more involved in its management. 
This is particularly true for chronic illnesses that require the patient to adhere to medical 
regimens in order to improve their outcome (as is the case with HSCT).  
1.9. PATIENT EDUCATION 
Patient education has been defined as a method of shaping behaviour in order to produce change 
in knowledge, attitudes, and skills required to sustain and improve health (Phillips, 1999). Patient 
education has generally been found to have a number of positive benefits for the patient (Fernsler 
& Cannon, 1991) in a range of illnesses, including cancer, rheumatoid arthritis, and chronic 
obstructive pulmonary disease (COPD). Positive outcomes of patient education have included 
improved knowledge about treatment and recall of information, increased patient participation in 
decision-making, better commitment to treatment, improved symptom management, greater 
satisfaction, increased ability to cope with illness, decreased length of hospital stay, reduced 
health care utilisation, less post-operative opioid use, reductions in anxiety and depression, 
improvement of symptoms (e.g. nausea, vomiting, pain), and enhanced quality of life (Fernsler 
& Cannon, 1991; McPherson, Higginson, & Hearn, 2001; Treacy & Mayer, 2000; Yoon, 
Conway, & McMillan, 2006). Patient education has been seen as an effective method of 
facilitating coping and encouraging patients to take more responsibility for their care following 
discharge from hospital. For cancer patients generally, education has been used with the aim of 
increasing knowledge as a way of alleviating helplessness and inadequacy (Fawzy, Fawzy, 
Arndt, & Pasnau, 1995). Furthermore, patient education can provide patients and their families 
with a sense of care and support (Yoon et al., 2006).  
1.9.1. THE EFFECT OF EDUCATION FOR OTHER ILLNESSES 
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Patient education has also been effective in improving outcomes with a range of illnesses and 
procedures such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD) and 
patients waiting to undergo cardiac catheterisation (Brus, Taal, van de Laar, Rasker, & 
Wiegman, 1997; Gurrud et al., 2001; Harkness, Morrow, Smith, Kiczula, & Arthur, 2003; 
Johnson, 1982). Patients with a chronic illness who took part in a 4 week patient education 
course reported less anxiety and a greater sense of meaning in their lives compared to those who 
did not participate in the course (Johnson, 1982). Similar to the waiting period for 
transplantation, waiting for elective cardiac catheterisation has been found to produce increased 
levels of anxiety and reduce perceived quality of life (Harkness et al., 2003). Harkness and 
colleagues (2003) found that an early education session provided by nursing staff during the 
waiting period was effective in reducing anxiety levels compared to controls. Gurrud, Wood, and 
Stainsby (2001) compared the effects of two patient education leaflets for women undergoing an 
elective laparoscopy. One leaflet contained detailed information about potential adverse 
consequences of the treatment. Women who received the leaflet that contained more risk 
information reported greater knowledge of all aspects of the treatment, higher satisfaction with 
information and no difference in anxiety compared to women in the control group. Furthermore, 
there was no evidence that patients that read the detailed education leaflet were less likely to 
proceed with the treatment. Thus, the authors concluded that providing detailed information 
about the risks of treatment does not appear to be detrimental in terms of anxiety but rather it 
may be beneficial in terms of increasing knowledge and satisfaction. Notwithstanding, the 
authors maintain that it is not known whether these results would generalise to providing detailed 
risk information for more life-threatening and risky procedures and treatments (Gurrud et al., 
2001).  
1.9.2. THE EFFECT OF EDUCATION ON ONCOLOGY PATIENTS 
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In an attempt to address the information needs of patients with cancer, a number of methods have 
been used to educate patients including the provision of written material, telephone help lines, 
teaching and audiovisual aids, interactive media, and patient education programmes (McPherson 
et al., 2001). A prospective study of an interdisciplinary psychoeducational intervention in a 
German acute cancer clinic randomly assigned cancer patients with various illnesses to an 
intervention or control group (Gundel, Lordick, Brandl, Wurschmidt, Schussler, Leps et al., 
2003). The intervention focussed on health education and coping skills. The results showed 
significant differences for the intervention group compared to the control group in terms of 
increased knowledge and better emotional functioning two months after the intervention. Four 
months after the psychoeducational program, patients in the intervention group continued to 
show an increase in knowledge, were more emotionally stable and were less inclined to engage 
in rumination compared to controls. Gundel and colleagues (2003) concluded that short-term 
interdisciplinary interventions can be helpful for improving knowledge and emotional 
functioning in cancer patients.  
 
A study that looked at the effect of an information booklet on patients with Hodgkin’s disease 
found that patients who received the information booklet demonstrated greater knowledge, less 
treatment problems and lower anxiety compared to the control group (Jacobs, Ross, Walker, & 
Stockdale, 1983; Treacy & Mayer, 2000). Anxiety is frequently examined as an outcome 
measure of patient education in cancer patients because (like HSCT) cancer and its treatments 
have been found to be associated with increased anxiety for patients and families (Fernsler & 
Cannon, 1991). Similarly, a study that examined the effect of an orientation program for patients 
who had just received a cancer diagnosis (McQuellon et al., 1998) found that patients who were 
assigned to the orientation program were more satisfied with their care, were more 
knowledgeable about the clinic and reported reduced anxiety, depression and overall distress one 
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week later. The orientation involved a tour of the clinic, information, and participation in a 
question and answer session with the oncology counsellor.  
 
Using a quasi-experimental time series design, Poroch (1995) compared two groups of cancer 
patients who were about to undergo radiation therapy. The intervention group received two 
structured teaching sessions that involved sensory and procedural education about the treatment, 
whereas the control group received the standard information. The intervention group were found 
to be less anxious and more satisfied during treatment than the control group and this result was 
maintained for up to seven weeks. Similarly, patients undergoing chemotherapy who received 
education about self care also experienced decreased anxiety six weeks later (Dodd, 1988). A 
comparable study examined the effects of an education/orientation program for radiation 
treatment on patients and families (Cartledge & Haaga, 2005). The education program involved 
verbal and written information. The authors found no differences between the intervention and 
control group in terms of state anxiety, general distress, treatment adherence, or knowledge. 
However, the intervention group reported greater satisfaction with their care and they were more 
likely to make use of psychological services at the clinic or elsewhere. 
1.9.3. NEGATIVE OUTCOMES OF EDUCATION 
Although the vast majority of studies looking at variety of illnesses have reported reductions or 
no differences in patient anxiety levels as a result of information and education, there have been 
some findings that have shown that information and education can have a negative impact on 
patients. Brus, Taal, van de Laar, Rasker, and Wiegman (1997) carried out an evaluation of a 
patient education program for rheumatoid arthritis patients, comparing the effect of education on 
high disease activity patients versus low disease activity patients. Four months after participating 
in the education program, patients with high disease activity showed greater levels of anxiety and 
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depression compared to controls. On the other hand, patients with low disease activity had lower 
levels of anxiety following education. 
 
In the field of oncology generally, there are still many aspects about the illnesses and related 
treatment that are not completely understood (Freedman, 2002). Thus, it could be confronting for 
patients to front up against the relative uncertainty and limitation of their prognosis. There is 
evidence to suggest that some patients do not want to be fully informed about their treatment and 
prognosis (Hagerty et al., 2004). Patients with lower education, patients from ethnic minorities, 
highly anxious patients and patients with a worse prognosis are more likely to want only positive 
information about their illness and prognosis and may prefer to leave treatment decisions to their 
doctor (de Haes, 2006; Hagerty et al., 2004). The degree of desire for information, level of 
education, cultural background and socio economic status are factors which have also been 
found to influence the degree to which patients seek out information (Harris, 1998). Hagerty and 
colleagues (2004) looked at information needs among 126 patients with metastatic cancer. 
Although the majority of patients (95%) wanted to be fully informed about their prognosis, less 
than half of the patients wanted to know their survival estimate in quantitative terms. Patients 
who had a poorer prognosis were less likely to want to know how long they were expected to 
live. Likewise, a large survey of cancer patients revealed that patients who reported higher levels 
of anxiety and those with a worse prognosis had less desire for information (Kaplowitz, Campo, 
& Chiu, 2002). On the other hand, cancer patients have been shown to be more satisfied when 
shared decision-making is achieved even when they did not want it to begin with (Gattelari et al., 
2001). The research suggests that in some circumstances information may be detrimental to 
psychological functioning when prognosis is less positive, which may have implications for 
HSCT patients. 
1.9.4 PATIENT EDUCATION AND HSCT 
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From the moment that the patient is considered as a potential candidate for transplantation, 
education becomes an important issue. Patients are likely to have questions about the transplant 
procedure, the possible effects or consequences of the treatment, the course of treatment and 
their expected quality of life post treatment (Franco et al., 1996). Some patients may have 
already sought out information themselves via the internet and as a result may be either well 
informed or misinformed depending on the source of the information (Blume & Amylon, 1999). 
However, it has been noted that HSCT patients often have an inadequate understanding of their 
disease  and are inclined to overestimate their prognosis which impacts on communication about 
life-threatening transplant options (Stiff, Miller, Mumby, Kiley, Batiste, Porter et al., 2006). A 
qualitative study of HSCT patients who had undergone treatment reflected that they would have 
liked to have more information about what to expect, such as information about others’ 
experiences, as this would have helped to reduce uncertainty and distress (Rini, Lawsin, Austin, 
DuHamel, Markarian, Burkhalter et al., 2007).  
 
HSCT is likely to be one of the most physically and psychologically traumatic events of a 
person’s life (Blume & Amylon, 1999). Therefore, education may be useful in preparing patients 
and families for a process that is likely to be prolonged and difficult (Franco et al., 1996). It has 
been argued that education that prepares patients and families for what to expect at the different 
stages of the HSCT process can be useful in relieving anxiety and fear of the unknown (Baker, 
1994). Furthermore, it is thought that the medical team would be more able to assist the patient 
through the HSCT experience if patients know what to expect from the different stages of 
treatment, understand the rationale for diagnosis and treatment, are aware of the significance of 
adverse events, and realise the overall risk (Blume & Amylon, 1999).  
 
Traditionally, patient education about HSCT was provided by the patient’s primary physician. 
Since then various methods have been used for educating patients, families and donors about 
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HSCT including scripts, booklets, videotapes, and computerised materials (Whedon & Fliedner, 
1999). More recently, group education programs supported by visual aids have been designed by 
transplant centres and hospitals which perform high volumes of HSCT in order to educate 
transplant candidates, families and carers about the transplant procedure, possible benefits, risks, 
and side effects, the course of treatment and the long term outcomes (Franco et al., 1996; Johns, 
1998; Whedon & Fliedner, 1999). Because of the complexity of HSCT, these educational 
programs are typically provided by a multidisciplinary team involving physicians, nurses, 
specialists, and nurse coordinators (Downs, 1994; Johns, 1998). Patients, families and carers are 
also given information about technical aspects such as care and maintenance and medication 
(Franco et al., 1996). Immuno-suppressive regimens, central venous line care and maintenance, 
dressing changes, and medications are some examples of the technical skills that patients and 
carers need to be taught (Franco et al., 1996). Baker (1994) argues that for education to be 
effective in HSCT it needs to be provided by a multidisciplinary team and be provided 
throughout the treatment process. Therefore, although major authors all endorse such 
programmes, and they have developed in many major centres, no form of education in education 
in HSCT has been tested. Despite the assumption that multidisciplinary patient education 
programs are effective in HSCT, to date there have been no empirical evaluations to support or 
refute this assumption. 
 
Informing patients about the possible adverse side effects of a treatment is a primary aim of 
providing patients with information (Gurrud et al., 2001). Due to the high level of risk associated 
with HSCT, education of the patient and family is considered to be an essential component of 
patient care (Downs, 1994; Franco et al., 1996). Stewart (1999) maintains that transplant 
treatment centres need to be absolutely honest about the risks of HSCT. HSCT requires that 
patients are cooperative, knowledgeable and aware (Blume & Amylon, 1999). Regret, 
complaints and legal recourse are potential outcomes for patients who are not adequately 
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informed about the risks associated with the proposed treatment. However, professionals can be 
hesitant to divulge all the possible adverse consequences of a treatment on the basis that they 
believe that patients are not interested in knowing about every possible outcome and/or that risk 
information could result in increased anxiety or rejection of necessary treatment (Gurrud et al., 
2001). It has been suggested that the educational process can have a negative effect on the 
patient’s emotional state (Stewart, 1999). However, Lesko (1994) noted that adult HSCT patients 
were not satisfied with only learning about the positive aspects of treatment. The needs of 
individual patient and family and the patients’ ability to use the information should be 
considered when deciding what to communicate (Baker, 1994). 
 
It has been argued that it may be unrealistic to expect patients to take on board the full range of 
potential consequences and risks of undergoing HSCT (Thomas, 1983). Haberman (1988) has 
also highlighted the fact that HSCT patients tend to have a poor understanding of the HSCT 
process and what to expect of themselves despite receiving an extensive amount of information 
from the multidisciplinary team. A study examining informed consent in adult bone marrow 
transplant patients, parents of paediatric bone marrow transplant patients, and the physicians, 
found that the majority of adults remembered less than half of the possible treatment 
complications (Lesko, Dermatis, Penman, & Holland, 1989). Interestingly, despite the fact that 
physicians believed that the information provided was too technical, the majority of the adults 
reported being satisfied with the information they received and that they did not find the 
information to be too technical. Another study of adult HSCT candidates examined 99 patients 
understanding of their disease through a survey before and after a 3 hour consultation (Stiff et 
al., 2006). Prior to the consultation, 23% of patients felt they had enough information to make an 
informed decision about HSCT, whereas post-consultation this had risen to 67%. Fifty four 
percent of these patients reported a significant reduction in the need for more information after 
the consultation. Stiff et al. (2006) concluded that, although investigating methods of increasing 
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patient understanding of disease and prognosis was justified, a 3 hour consultation visit is 
sufficient for making an informed decision about HSCT for the majority of patients. Despite the 
positive results of a three hour consultation, it is interesting that 33% still did not feel that they 
had enough information to make an informed decision and that nearly half of the patients felt 
that they needed more information. This makes a strong argument for longer multi-disciplinary 
education programmes. 
1.9.5. CARER AND FAMILY INFORMATION NEEDS 
Changes in doctor patient communication in recent times has resulted in the patient no longer 
being viewed as the passive recipient of information but rather one element of the patient-
caregiver partnership (Adams, 1991). Despite this emerging attitude, the lack of effective 
communication with members of the healthcare system has been reported to be a major 
contributor to caregiver stress (Krasuska, 2002). In particular, caregivers have pointed out that 
they need more information about the complex skills needed to care for the patient post-
transplant. In line with this, it has been argued that the primary carer needs to be central to the 
decision-making process as they play such an important role in the patient’s care after 
transplantation (Franco et al., 1996). Rehabilitation and cooperation with self-care has been 
shown to be poorer when the family is left out of the education process; particularly for acutely 
and chronically ill patients (Phillips, 1999). Thus, there is a strong argument for the inclusion of 
families in patient education, regardless of whether the education is given in the hospital setting 
or the home. To date, there had been no studies that have looked at the effects of educational 
methods on the HSCT patient’s family or caregiver. Not surprisingly then, there is a considerable 
need for empirical evidence evaluating interventions for carers of HSCT patients. 
1.10. SIGNIFICANCE OF CURRENT STUDY 
As a result of the evidence supporting patient education in oncology, education programs are 
considered best practice and as such have proliferated. However, because HSCT is a relatively 
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rare procedure, and has a considerably poorer prognosis than other cancer treatments 
(particularly allogeneic HSCT), we cannot assume that these programs are helpful and to date 
they remain untested. Indeed, the results of education programs in other settings may not 
generalize to these patients and may even be harmful for some patients. For example, because 
HSCT is so rare, in practice education programs typically combine patients receiving allogeneic 
and autologous HSCT. It is possible that having a combined information day for autologous and 
allogeneic HSCT patients will result in decreased anxiety for the low risk group (autologous) but 
increased anxiety for the high-risk group (allogeneic). As discussed, in a small number of 
studies, patients with poorer prognosis have been found to experience greater distress as a result 
of educational programs. On the other hand, it is equally possible that patients awaiting 
autologous transplants will not distinguish between the information that is relevant to them and 
the information relevant to patients awaiting allogeneic HSCT. This may inadvertently increase 
anxiety in the low risk (autologous) group. Additional information has been suggested to 
increase anxiety, especially when it is confusing or misunderstood (de Haes, 2006). Targeting 
information to the individual patient can help reduce the amount of information that needs to be 
taken in and ensures that the patient only receives information that is relevant to them 
(McPherson et al., 2001). This has been found to have positive effects on recall, patient and carer 
satisfaction, anxiety and sense of meaning and purpose in life. At this stage, the effect of 
educational programs on HSCT patients is not known. Intuitively, having a multidisciplinary 
team discuss all aspects of HSCT may help to reduce patient distress because patients may feel 
more supported in their illness. However, without research into the efficacy of education 
programs, the effect of education in the area of HSCT will remain an empirical question.   
 
This study aims to provide the first evaluation of a group patient education programme for 
patients undergoing HSCT and their carers. The questions that will be examined by this research 
are: (1) What are the rates and correlates of distress in HSCT patients and carers, (2) What effect 
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does education have on patients and carers and (3) Is there a relationship between knowledge 
following the education programme and distress?  
 
The primary goal of the education intervention is to increase knowledge. Based on the existing 
literature it was hypothesised that patients and carers who received the education programme 
would have higher levels of knowledge not evidenced in a group waiting to receive the 
programme. The secondary objective of the intervention was to ensure that the education 
programme did not result in any adverse effects for patients and carers. Based on the literature 
review, it was hypothesised that the education program would not lead to increased anxiety and 
depressive symptoms. Furthermore, we predicted that patients who knew more about their 
condition would be less distressed. It was also of interest to investigate other outcomes likely to 
be effected by the intervention such as support, information satisfaction, patient illness 
perceptions and caregiver burden. Thus, this thesis has two empirical studies. Chapter 1 
investigates the psychosocial sequelae and correlates of HSCT for patients and carers and 
Chapter 2 examines the effectiveness of the intervention using a randomised control trial of the 
HSCT education programme. 
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CHAPTER 2: RATES AND CORRELATES OF DISTRESS 
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2.1. INTRODUCTION 
Psychopathology and Cancer 
A diagnosis of cancer is a frightening experience; associated with uncertainty and a range of 
understandable psychological sequelae. The National Comprehensive Cancer Network (NCCN) 
guidelines define distress as affect experienced by people as a result of their experience of cancer 
and its treatment (NCCN, 1999). According to this definition, distress can range from sadness 
through to more severe and clinically significant symptoms characteristic of psychiatric 
diagnoses. It is known that a significant proportion of cancer patients experience high levels of 
psychopathology. Research examining patient distress in oncology has revealed clinical levels of 
distress in approximately a third of patients (Zabora et al., 2001). Rates of psychopathology vary 
according to type of cancer, prognosis and burden of illness. For instance, a higher prevalence of 
distress was found in lung cancer patients (43.4%) compared to those with gynaecological 
cancers (29.6%) (Zabora et al., 2001). However, patients experiencing distress do not necessarily 
come to the attention of hospital staff as there is considerable evidence that distress is under-
detected in clinical settings (Lee, Loberiza, Antin, Kirkpatrick, Prokop, Alyea et al., 2004). 
Therefore, assessing patients for clinical levels of distress early on is important. Psychopathology 
or distress associated with cancer treatment has been found to negatively impact on patients’ 
quality of life, symptom related-distress, adherence to care regimens, and disease-free survival 
(Colon et al., 1991; Goetzmann et al., 2007; Hann et al., 1997; Sutherland et al., 1997).  
Psychopathology in HSCT 
In high-risk groups, such as patients having HSCT, rates of distress appear to be higher than in 
other cancer patients (Trask et al., 2002). This is not surprising given the higher risk of mortality 
and the stressful side effects associated with this treatment which include: GvHD (acute and 
chronic), infection, cataract formation, pulmonary and neurological complications, gonadal 
failure, infertility, relapse and secondary malignancy (Andrykowski & McQuellon, 1999; Langer 
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et al., 2003; Lesko, 1994). Research on psychological distress experienced by HSCT patients has 
indicated that approximately 50% of patients experience clinical levels of distress prior to 
receiving information about their treatment (Trask et al., 2002). This rate is also consistent with 
distress levels assessed at other time points during the HSCT process (Neitzert et al., 1998). For 
instance, Leigh, Wilson, Burns and Clark (1995) found rates of clinical psychopathology in 54% 
of patients before and after treatment with HSCT. Six to nine months later, patients still rated 
highly on psychological distress. Fife et al. (2000) investigated emotional distress after admission 
to hospital and before HSCT infusion. These authors found that patients were most vulnerable to 
psychosocial distress during hospitalisation prior to HSCT. Three months and 1 year after 
transplantation were the time points that were associated with the least distress. The factors most 
likely to affect patients’ emotional distress and adaptation were degree of emotional distress at 
baseline, personal control, cognitive response, and symptomatology (physical and emotional 
symptoms). Keogh and colleagues (1998) found moderate to high levels of anxiety and 
depression in 61% and 14% of patients respectively pre-treatment. Similarly, Jenks Kettmann & 
Altmaier (2008) found clinical levels of depression in 29.1% before HSCT and 27.6% one year 
post-HSCT. These studies support the view that elevated levels of distress are common in HSCT 
patients throughout the treatment process. 
Rates of Disorder 
Although not all distressed patients fulfil criteria for some form of psychiatric diagnosis, a 
significant proportion of patients do. Twenty-eight percent of patients who had undergone HSCT 
described symptoms from pre-treatment that would have met criteria for clinical depression 
(Jenkins et al., 1991). These results were confirmed in a prospective study that found that 16% of 
patients met criteria for major depressive disorder pre-HSCT (Jenkins et al., 1994). This suggests 
that not only is general distress heightened in HSCT patients, but also severe symptoms 
sufficient to warrant diagnosis are also more common than in the general population. The poor 
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prognosis, demanding treatment, and wealth of physical complaints likely contribute to these 
elevated rates of psychological disorder and distress.  
Factors Associated With Distress 
Although rates of distress and disorder are higher in HSCT patients than controls, the majority of 
patients do not experience clinical levels of psychopathology. Hence, it is of interest to 
determine what factors may be associated with levels of distress as this may help to identify 
effective interventions. The way patients perceive their illness has been found to influence 
patient behaviour and emotional reactions in other illnesses (Weinman & Petrie, 1997). In 
relation to cancer patients, illness perceptions have been found to have important effects on 
quality of life in patients diagnosed with head and neck cancer (Scharloo, Baatenburg de Jong, 
Langeveld, van Velzen-Verkaik, Doorn-op den Akker, & Kaptein, 2005). HSCT patients appear 
to be most likely to attribute causal attribution of their illness to chance rather than themselves or 
others (Frick et al., 2006). However, those that did attribute the cause of their illness to 
themselves were more distressed. More research is needed regarding the illness perceptions of 
HSCT patients and their relationship to patient distress.  
 
Satisfaction with information and social support are factors that have been indentified as being 
associated with less distress in cancer patients. Perceived lack of information about treatment has 
been found to be associated with increased anxiety, uncertainty, dissatisfaction, distress and poor 
treatment decisions (Fallowfield et al., 1995; Gamble, 1998). Social support has been highlighted 
as a potentially significant factor for patients undergoing HSCT (Jenks Kettmann & Altmaier, 
2008). Jenks Kettmann & Altmaier (2008) found perceived social support pre-transplant 
significantly predicted levels of depression one year post-HSCT over and above pre-transplant 
depression. Another study of HSCT patients found an association between stable social support, 
increased survival and better quality of life post-transplant (Rodrigue, Pearman, & Moreb, 1999). 
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Patients generally see their partner and friends as their primary sources of social support. 
However, hospital staff can also come to play an important role. Frick, Motzke, Fischer, Busch, 
and Bumeder (2005) found significant increases in perceived social support from health care 
professionals from pre-HSCT to the period directly before transplant when patients were 
receiving large doses of chemotherapy. 
Carer Distress 
The illness and its treatment are demanding not only for the patient but also for members of their 
immediate family. Family and carers of HSCT patients have been found to experience significant 
interpersonal and personal distress throughout the transplantation process (Krasuska et al., 2002). 
There have been relatively few studies that have looked at the psychosocial effects of HSCT on 
caregivers. One study that assessed relatives of HSCT patients using the General Health 
Questionnaire (GHQ) found 88% scored above the stress threshold at pre-treatment (Keogh et 
al., 1998). Family members’ distress reduced over time with 62% at three months, 40% at six 
months, and 18% at twelve months scoring above the clinical threshold. However, the GHQ is a 
measure of overall health and therefore while this indicates carer distress, the nature of that 
distress is unclear. Foxall and Gaston-Johansson (1996) also investigated HSCT caregivers 
levels of anxiety. One week prior to HSCT, caregivers were found to have, on average, moderate 
levels of anxiety on the State Trait Anxiety Inventory (STAI). These heightened levels of anxiety 
did reduce over time. Notably, these authors did not find elevated rates of depression in carers. 
Carers of HSCT patients have identified fatigue, disruption to everyday life and financial strain 
as the major sources of burden (Foxall & Gaston-Johansson, 1996). In HSCT and cancer 
generally, greater burden has been found to be associated with worse health outcomes for carers, 
including increased levels of distress (Foxall & Gaston-Johansson, 1996; Grunfeld et al., 2004).  
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Aims and Hypotheses 
While it is well documented that patients have higher levels of distress than controls, carer’s 
distress is less well understood. The primary purpose of this chapter was to examine the baseline 
rates of psychopathology in HSCT patients and their primary carers prior to undergoing 
treatment and to investigate correlates of heightened levels of distress. Knowledge of factors 
associated with elevated distress may be useful in understanding what elements of an education 
programme will be most helpful to patients and carers. It was hypothesised that both patients and 
carers would experience elevated levels of distress. 
2.2. METHOD 
2.2.1. PARTICIPANTS 
The participants were a consecutive sample of patients awaiting HSCT and planning to attend an 
education program at Westmead Hospital, a major transplant centre. Patients nominated a 
primary carer who was also planning to attend the HSCT education program. Details of 
recruitment are specified in Chapter 3. Seventy-five patients were sent out a research information 
statement or were informed about the study by the Transplant Coordinator. Patients who were 
non-English speaking were excluded. Thirty-six patients gave permission to be contacted by a 
researcher, which was followed up by telephone. Of those contacted, thirty-two agreed to take 
part. Twenty-nine of these patients had carers who participated. One carer of a patient who was 
non-English speaking participated without the patient. Written consent was obtained at the 
education day.  
2.2.2. PROCEDURE 
Patients were sent information about the study with their invitation to attend the education 
program or were asked by the Transplant Coordinator over the telephone if they would agree to 
be contacted about the research. Those who agreed were contacted by the researcher who sought 
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verbal consent to take part. Patients and carers were administered a battery of questionnaires via 
telephone, which took approximately 20 minutes for patients and 10 minutes for carers. All 
patients and carers completed these assessments before receiving the education program.
2.2.3. MEASURES 
The assessment measures were chosen due to their psychometric properties, length of time to 
complete and ease of administering via telephone. See Table 1 for a list of assessment measures. 
Table 1. Assessment Measures 
List of Measures Completed By 
Hospital Anxiety and Depression Scale Patients and Carers 
Distress Thermometer Patients and Carers 
Brief Illness Perception Questionnaire Patients 
Information Satisfaction Questionnaire Patients 
DUKE Functional Social Support Questionnaire Patients 
Caregiver Reaction Assessment Carers 
 
Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) 
The HADS is a 14-item self-report screening measure designed to detect depressive and anxiety-
related symptomatology in medical patients. The scale may be used to assess change in a 
patient's emotional state as well as for assessing presence or absence of clinically significant 
degrees of anxiety and depression (Zigmond & Snaith, 1983). Patients are asked to assess each 
item in the context of how they have felt over the past week. Each item is rated on a four-point 
scale, with a higher score indicating greater state depression and/or anxiety. There are two 
subscales, anxiety and depression, consisting of 7-items each. Combined raw scores for each 
scale range from 0 to 21. Scores can be categorised as normal (0-7), possible clinical disorder 
(8+), or probable clinical disorder (10+) (Zigmond & Snaith, 1983). The items on the depression 
subscale tap into anhedonic symptoms whereas the items on the anxiety subscale measure 
affective and cognitive symptoms more than somatic symptoms (Campbell & Martin, 1994). In a 
study of 568 cancer patients, the reliability of each subscale was found to be high: depression (r 
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= 0.90) and anxiety (r = 0.93) (Moorey, et al., 1991). Moorey and colleagues (1991) found two 
distinct, but correlated, factors corresponding to anxiety and depression. The internal consistency 
of the two subscales was also high. For the purposed of the analyses, the depression and anxiety 
subscales were used to examine patient and carer distress.  
National Comprehensive Cancer Network Distress Thermometer (DT;1999) 
The DT is a one-item screening tool for assessing distress in cancer patients. Patients are asked 
to rate their level of distress over the past week based on a rating scale used to measure pain: 0 
(no distress) to 10 (extreme distress). Originally, a cut-off score of 5 or above (moderate distress) 
was suggested for identifying a need for intervention. Although, more recent studies, including a 
study validating the DT for patients about to undergo HSCT, have used a cut-off score of 4 or 
above (Ransom, Jacobsen, & Booth-Jones, 2006). Psychometric studies have shown good 
reliability (0.81) and validity of the DT as a rapid screening measure for distress associated with 
cancer treatment. It compares well with longer psychological measures of distress. It is well 
correlated with the HADS total score and the anxiety subscale; the depression subscale is not as 
well correlated (Trask et al., 2002). For the purposes of this study, a cut-off score of 5 or above 
was used. 
2.2.4. PATIENT MEASURES 
Brief Illness Perception Questionnaire (BIPQ) (Broadbent, Petrie, Main, & Weinman, 
2006) 
The BIPQ is a short nine-item scale designed for taking a quick assessment of cognitive and 
emotional perceptions of illness. The BIPQ is a brief version of the well-validated Illness 
Perception Questionnaire (Weinman et al., 1996). The IPQ examines the cognitive 
representations patients make of their illness and focuses on five major themes that research has 
identified as pertinent: Identity, Cause, Time-line, Consequences, and Cure/control. The revised 
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version (IPQ-R) incorporated more items including understanding, emotional impact, cyclical 
time line and also distinguished between personal and treatment control (Moss-Morris, 
Weinman, Petrie, Horne, Cameron, & Buick, 2002). The BIPQ taps into the original five 
constructs plus the additional four from the IPQ-R. It is recommended for very ill patients 
because it usually takes only a couple of minutes to complete (Petrie et al., 2007). Patients are 
asked to rate how much each item applies to them on a 10-point scale. It has demonstrated good 
test–retest reliability (ranging from .48 to .70 for the 9 scales) and concurrent validity (Broadbent 
et al., 2006). Cause of illness was not considered appropriate for this study so only the first 8 
items were used. In order to make the questionnaire specific to the sample population under 
investigation, the word “illness” was replaced with “transplant” or “condition” accordingly. 
Information Satisfaction Questionnaire (ISQ) (Thomas, Kaminski, Stanton, & Williams, 
2004) 
The ISQ is a brief scale designed to assess the general information satisfaction of cancer patients. 
The questionnaire includes one item assessing information needs on a 3-point scale, a yes/no 
item asking if information could have been improved and 6 items examining satisfaction with 
specific categories of information. These 6 items ask about satisfaction with information 
provided about the illness, possible side effects, treatment options and relative benefits, lifestyle 
issues (e.g. support groups), practical issues (e.g. parking and follow-up plans) and overall 
satisfaction. Patients rate each item on a 5-point Likert scale from 0 = not satisfied to 4 = very 
satisfied. For this study, a total satisfaction score was created by taking the mean of the first five 
items. No studies have been conducted to validate this measure. However, given the focus of this 
research on education, it has considerable face validity.  
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Duke-University of North Carolina Functional Social Support Questionnaire (FSSQ) 
(Broadhead, Gehlbach, de Gruy, & Kaplan, 1988) 
The Duke-UNC Functional Social Support Questionnaire is a brief 8-item self-report measure 
designed to assess a person’s satisfaction with functional and affective social support. It consists 
of two scales, Confidant Support (i.e., general emotional support from family and friends) and 
Affective Support (i.e., support from those identified as a confidant with whom [s]he feels free to 
discuss any problems). Responses to all questions were rated on a 5-point scale ranging from 1 = 
much less than I would like  to 5 = as much as I would like.  Internal consistency ranged from 
.50 for useful advice to .85 for help around the house (Broadhead, Gehlbach, de Gruy, & Kaplan, 
1989). This test has been shown to have good reliability (.66) but low convergent validity 
(McDowell, 2006). 
2.2.5. CARER MEASURES 
Caregiver Reaction Assessment (CRA) (Given et al., 1992) 
Consisting of 24-items, the CRA aims to assess caregiver experiences in five domains: daily 
schedule, financial situation, relationships with others, physical health and self-esteem. Each 
subscale is added to a sum score, which is divided with the number of items, reflects the 
unweighted mean-item score with a range from 1.0 to 5.0. A total CRA score was created by 
taking the mean of the five scales. The self-esteem dimension was recoded because the original 
score meant a high score indicated positive reactions to caregiving. After this recoding, the CRA 
total score could be interpreted as a dimensional scale of the caregiver situation where higher 
scores reflect higher burden. The CRA has been found to have sound psychometric properties 
when applied to carers of cancer patients (Nijboer, Triemstra, Tempelaar, Sanderman, & van den 
Bos, 1999). The original paper examined caregivers looking after late palliative stage cancer 
patients (Grov, Fossa, Tønnessen, & Dahl, 2006). In their sample the total CRA score was 11.37 
(SD = 2.1). The internal consistency of the subscales of the CRA have been demonstrated to 
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range between 0.57 (finances) and 0.85 (self-esteem) and the coefficient of the CRA total scale 
has been shown to be high at 0.74 (Grov et al., 2006).  
2.2.6. DATA ANALYSIS 
Scores were created to differentiate clinical and non-clinical levels of anxiety and depression for 
patients and carers’ anxiety and depression subscales on the HADS pre transplantation. The 
scores were created based on clinical and non-clinical levels of depression and anxiety, with 
scores of 0 to 7 on both scales recoded as 0 and scores 8 to 12 recoded as 1. A similar score was 
created using the DT for patients and carers, with a score of five or more indicating clinical 
levels. Frequencies were conducted to obtain percentages of clinical levels of depression, anxiety 
and distress (see Appendix D for statistical analyses). Correlations were also conducted to look 
at the relationships between distress and the other patient measures (BIPQ, ISQ and DUKE-
UNC) using Pearson’s Correlation Coefficient. Patient and carer comparisons for the distress 
measures will be conducted using paired t-tests. 
2.3. RESULTS 
2.3.1. DEMOGRAPHICS 
Thirty-two patients with various illnesses (see Table 3) and thirty carers completed the measures 
pre treatment. Of the patients, 21 (65.6%) were male and 11 (34.4%) were female. There were 10 
(32.3%) male carers and 21 (67.7%) female carers The mean age for patients was 46.84 
(SD = 11.64) (range = 22 – 71) and 46.32 (SD = 11.45) (range = 24 – 74) for carers. Illness 
length ranged from one to 66 months, with a mean length of 11.56 (14.81) months. Most patients 
(93.8%) had children, and 59.4% had children who were under 18 years. Similarly, 93.5% of 
carers had children, with 58.1% under 18 years of age. Most carers were spouses (87.9%). 12.2% 
were the patients’ sibling or child. See Table 2 for other demographic information on the sample. 
  54
Table 2. Patient and carer demographic and medical characteristics 
  Patient (n = 32) Carer (n = 31) 
  No. % No. % 
Marital Status Married/living with partner 30 93.8 26 86.7 
 Single/separated/divorced/widowed 2 6.3 4 13.3 
Ethnicity Caucasian 26 81.3 26 83.9 
 Asian 3 9.4 2 6.5 
 Hispanic 2 6.3 2 6.5 
 Other 1 3.1 1 3.2 
Occupation Managers/Administrators 1 3.1 0 0 
 Professionals 9 28.1 10 32.3 
 Associate Professionals 3 9.4 4 12.9 
 Tradespersons 8 25 0 0 
 Advanced clerical/service 3 9.4 2 6.5 
 Intermediate clerical/sales/service 6 18.8 5 16.1 
 Intermediate production/transport 2 6.3 3 9.7 
 Elementary clerical/sales/service 0 0 1 3.2 
 Labourers 0 0 1 3.2 
 Unemployed/Pension 0 0 5 16.1 
Working Yes 9 28.1 21 67.7 
 No 21 65.6 9 29 
 Retired 2 6.3 1 3.2 
 
Table 3: Patient illness diagnosis characteristics 
Diagnosis     
Leukemia (AML, ALL, CML) 19 59.4   
Lymphoma (Hodgkin’s, non-Hodgkin’s 6 18.8   
Multiple Myeloma 4 12.5   
Myelodysplastic Syndrome 3 9.4   
2.3.2. DEPRESSION 
The means and standard deviations for depression, anxiety and distress are presented in Table 4. 
The mean for patients on the HADS depression subscale was 6.42 (SD = 4.05). Based on a cut-
off point of 8 on the HADS, 61.3% of patients had non-clinical levels of depression and 38.7% 
had levels indicative of clinical depression (see Table 5). The mean HADS depression score was 
6.67 (SD = 4.13) for carers. Sixty percent of carers scored in the non-clinical range for 
depression and 40% had clinical levels of depression.  
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Table 4: Means (and standard deviations) of patient and carer psychopathology  
HADS & DT Means & SDs Patient Carer 
 Mean SD Mean SD 
Depression (HADS) 6.44  3.98 6.79  4.14 
Anxiety (HADS) 7.35  4.44 10.21  4.19 
Distress Thermometer (DT) 4.03  2.54 5.24  2.20 
2.3.3. ANXIETY 
The mean HADS anxiety score for patients was 7.35 (SD = 4.44). Based on a cut-off point of 8, 
51.6% of patients scored in the non-clinical range for anxiety and 48.4% scored in the clinical 
range. The mean HADS anxiety score was 10.03 (SD = 4.22) for carers. Using the same cut-off 
point, 70% of carers had clinical levels of anxiety and 30% were in the non-clinical range.  
Table 5: HADS & DT cases  
HADS & DT Cases Patient Carer 
 No. % No. % 
Depression (HADS) 12 38.7 12 40 
Anxiety (HADS) 15 48.4 21 70 
Distress Thermometer (DT) 11 34.4 21 70 
Note: A case is defined as a score >7 in either the anxiety or depression HADS subscales and >5 on DT. 
2.3.4. DISTRESS 
The mean DT score for patients was 4.03 (SD = 2.54). Based on a cut-off point of 5, 64.5% of 
patients were in the non-clinical range for distress and 35.5% were in the clinical range. For 
carers, the mean DT score was 5.24 (SD = 2.20). Seventy percent of carers were in the clinical 
range for distress and 30% were in the non-clinical range.  
2.3.5. PATIENT ILLNESS PERCEPTIONS 
Patients were assessed on the eight illness perception items. Means and standard deviations of 
each scale are reported in Table 6. Each of the eight items was examined to see whether they 
were related to any of the other patient measures (see Table 7 for significant correlations). 
Interestingly, patient depression was positively associated with consequences, illness identity 
(degree and severity of symptoms), and emotional response. Patient anxiety was positively 
related to timeline, concern and emotion. Distress was correlated with identity, concern, and 
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emotion. Data on the illness perceptions of myocardial infarction (MI) patients from Broadbent 
and et al’s (2006) study are included in Table 6 in order to see how HSCT patients compared to 
other patient groups. In comparison to MI patients, HSCT patients appear to report greater 
consequences, concern and emotional response in relation to their illness. They also perceive 
their illness will continue for less time and feel that they have less personal control.  
Table 6: Brief IPQ mean scores in HSCT and MI patients 
 HSCT MI T-Score Sig. (2-tailed) 
Consequences* 7.55 (2.08) 4.1 (2.8) 9.235 .000 
Timeline* 4.20 (2.82 7.2 (3.1) -5.825 .000 
Personal Control* 3.10 (3.22) 7.7 (1.7) -7.964 .000 
Treatment Control 8.84 (1.67) 8.8 (1.2) .148 .883 
Identity* 4.28 (3.06) 3.1 (2.6) 2.442 .021 
Concern* 8.44 (2.08) 6.2 (3.4) 6.491 .000 
Understanding 7.81 (2.09) 8.0 (2.2) -.509 .615 
Emotional Response* 6.28 (2.28) 4.2 (3.1) 5.175 .000 
MI data from Broadbent et al. (2006) 
 
Table 7: Correlations between distress, BIPQ, ISC and DUKE-UNC 
Correlations     
 Subscales Depression Anxiety Distress 
BIPQ Consequences .506** -.227 .205 
 Timeline .255 .394* .297 
 Personal Control -.123 -.110 .138 
 Treatment Control -.290 -.195 -.093 
 Identity .513** -.226 .348 
 Concern .182  -.273  .416* 
 Understanding .197 .046 .032 
 Emotional Response .342  -.121  .589**  
ISC Information Satisfaction -.285 -.257  -.202  
DUKE-UNC Confidant Support .171 .084  .147 
 Affective Support .078 .107  .076 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
2.3.6. PATIENT INFORMATION SATISFACTION 
A total score for information satisfaction was created by taking the mean of the five scales. 
Patients had a mean score of 2.82 (SD = 0.55). According to the means (see Table 8), patients 
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were most satisfied with treatment information (e.g. options available and relative benefits) and 
least satisfied with practical information (e.g. parking, transport and follow up plans). Overall, 
mean responses for all of the scales indicated that patient satisfaction ranged from two (not sure) 
to three (satisfied). The only significant correlation for the information satisfaction scales with 
the distress measures was for explanation of illness (i.e. diagnosis, outcome, and aggressiveness). 
Greater patient satisfaction with the explanation of their illness was associated with less distress 
(r(32) = -.37, p = .04).  
Table 8: Patient information satisfaction means & standard deviations (N=32) 
Information Satisfaction  Means & SDs Mean SD 
Explanation of Illness 2.91 .89 
Information on Side Effects 3.06 .91 
Treatment Information 3.13 .75 
Lifestyle Information 2.53 .84 
Practical Information 2.47 .88 
Overall Satisfaction 2.78 .61 
2.3.7. PATIENT SOCIAL SUPPORT 
For confidant support, patients had a mean of 21.17 (SD = 3.76) and for affective support they 
had a mean of 14.53 (SD = 0.88). Based on the means, patients appeared to have more confidant 
support (e.g. opportunities to talk about problems and attend social activities) than emotional 
support (e.g. love, affection and care from others). These means were similar to those reported in 
a study of patients with early stage (0-II) breast cancer (Trunzo & Pinto, 2003). Baseline means 
from Trunzo and Pinto’s paper were 20.5 (SD = 4.5) for confidant support and 13.1 (SD = 2.4) 
for affective support. Neither confidant nor affective support were significantly correlated with 
the HADS or DT (see Table 7).  
2.3.8. CAREGIVER BURDEN 
The individual means and standard deviations for the five scales on the CRA are reported in 
Table 9. For the total score, carers had a mean of 15.29 (SD = 1.96) burden. This sample had 
significantly higher total burden (t(29) = 10.97, p < .000) compared to palliative cancer patients 
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(Grov et al., 2006). Comparisons of the means of the HSCT and palliative cancer (PC) patients 
for the subscales are listed in Table 9. Significant differences were found for all the scales except 
family support. Greater burden on carer health was associated with higher levels of carer 
depression (r(30) = .56, p = .001) and distress (r(30) = .42, p = .022). 
Table 9: Carer CRA HSCT & PC Means & SDs 
CRA Means & SDs HSCT Patients Palliative Patients T-Score Sig. (2-tailed) 
Self Esteem* 4.38 (.41) 2.1 (.6) 30.28 .000 
Family Support 1.99 (.76) 2.1 (.7) -8.22 .418 
Finances* 2.96 (1.07) 2.2 (.8) 3.86 .001 
Schedule* 3.50 (.77) 2.8 (1.0) 5.01 .000 
Health* 2.48 (.56) 2.2 (.6) 2.68 .012 
 Palliative cancer patient data from Grov et al (2006) 
2.3.9. COMPARISON OF CARERS AND PATIENTS 
Although rates of distress were expected to be high in both carer and patient samples, the levels 
in the carer sample were particularly high. In order to determine whether carers were more 
distressed than patients, three paired t-tests were conducted. There was no difference between 
patient and carer levels of depression, t(28) = -.470, p = .642. However, a significant difference 
was found between patient and carer anxiety, with carers having greater anxiety than patients, 
t(28) = -2.967, p < .01. Carers were also significantly more distressed than patients, t(28) = -
2.398, p < .05. Correlations were conducted between patient and carer distress measures (see 
Table 10). The DT was positively related to both HADS scales for carers, but only the 
depression subscale was positively correlated with the DT for patients. Patient depression was 
also associated with higher carer distress on the DT. 
Table 10: Patient & carer correlations on HADS & DT 
Correlations Carer DT Carer Anxiety Carer Depression Patient DT Patient Anxiety 
Patient Depression .382* .191 -.353 .534** .283 
Patient Anxiety .002 .180 -.089 .624**  
Patient DT .220 .198 .032   
Carer Depression .724** .699**    
Carer Anxiety .697**     
**  Correlation is significant at the 0.01 level (2-tailed).             *  Correlation is significant at the 0.05 level (2-tailed). 
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2.4. DISCUSSION AND CONCLUSION 
2.4.1. DISCUSSION 
The purpose of this chapter was to examine rates and correlates of distress in patients undergoing 
HSCT and their carers. It was hypothesised that levels of anxiety and depression would be 
elevated in both patients and carers and it was expected that clinically significant levels of 
distress would be common. These hypotheses were supported. Patient distress was shown to be 
elevated and of a level consistent with other studies on HSCT. Carer distress was also elevated. 
Furthermore, carers were found to be significantly more anxious than patients. 
 
The results indicated that there is significant emotional distress among patients prior to receiving 
HSCT. Almost half of the patients in our sample reported clinical levels of anxiety. Rates of 
depression were also substantial, with approximately 40% of patient reporting clinically 
significant depressive symptomatology. About 35% of patients had a cut of score in the clinical 
range on the DT, indicating a need for intervention. These findings correspond with the research 
on rates of distress in HSCT patients suggesting that patients undergoing HSCT experience 
greater distress than other cancer patients.  
 
The DT score was highly correlated with patient anxiety and depression, supporting its use as a 
brief screening measure in HSCT. However, there was surprisingly no correlation between 
anxiety and depression on the HADS. This finding is difficult to explain because normally 
anxiety and depression are significantly related. Although this result may be due to the small 
sample size and resulting lack of power, in most samples a correlation of between 0.5 and 0.8 is 
found between depression and anxiety. Whereas in this sample the correlation is only 0.28. It 
may be that anxiety is elevated for most patients due to the understandably anxiety-provoking 
nature of HSCT (even if for some these elevated symptoms fall below the cut-off point for 
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clinical distress). As such, the elevated anxiety scores across the sample may have obscured the 
usual relationship between depression and anxiety. The fact that the average anxiety score fell 
within the clinical range supports this view.  
 
In terms of the effect of HSCT on caregiver psychopathology, the results were surprising. The 
majority of carers (70%) had levels of anxiety in the clinical range prior to treatment. Carer 
distress, as assessed on the DT, revealed the same number of cases as the anxiety subscale of the 
HADS, with 70% indicating substantial distress. Again, the DT was highly correlated with carer 
anxiety and depression. Although it was expected that carers would have elevated levels of 
distress, the levels were even higher than anticipated. Post-hoc analyses comparing carers with 
patients showed that carers were significantly more anxious than patients. However, there was no 
difference in carers’ levels of depression, with around 40% of carers reporting clinically 
significant levels of depression. Although there is limited research on caregiver psychopathology 
in HSCT, Foxall & Gaston-Johansson (1996) also found that a high proportion of HSCT carers 
developed elevated levels of anxiety but not depression. Interestingly, carer distress was related 
to patient depression but there were no other significant correlations between patient and carer 
psychopathology variables. Since the primary carers are predominantly spouses of the patients, it 
is not surprising that if the carer is distressed that this will also affect the patients’ ability to cope 
emotionally. Patients are likely to rely heavily on their spouses for both emotional and practical 
support. 
 
Illness perceptions were found to be significantly higher in our sample compared to MI patients 
in Broadbent et al’s study (2006). HSCT patients perceived more consequences of their illness 
and symptoms, less personal control and had greater concern and emotional response in relation 
to their illness. They also perceived a shorter time frame for their illness compared to MI 
patients. These differences make sense because the impact of HSCT is greater and the patients 
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are more ill than in MI. Patients having HSCT are less likely to be able to have as much potential 
to improve their health as MI patients. For example, once someone has had an MI, the risk of 
future problems can be ameliorated through changes in lifestyle. This is not the case in HSCT. 
Therefore, although patients see less control, increased consequences, symptoms and emotional 
impact, this likely reflects the fact that HSCT is more serious.  Furthermore, the fact that HSCT 
patients perceive a shorter illness length is consistent with the expectation that the transplant will 
cure them of the disease, or at least control the spread of disease.  
 
Interesting relationships were found between patient illness perceptions and distress. Patient 
depression was positively correlated with consequences and identity. This result indicates that 
patients are more likely to experience higher levels of depression if they perceive their illness as 
being more serious and they experience more symptoms. It makes intuitive sense that patients 
would feel more depressed the more they perceive their illness as have a negative impact not 
only physically but also generally. Conversely, if patients are more depressed, they are more 
likely to focus on the consequences of the illness and symptoms. Not surprisingly, depression 
was also associated with emotional impact of the illness, as were anxiety and distress. Patients 
who were more anxious were more likely to perceive their illness continuing for longer and have 
greater concern about their illness. More research is needed to understand the meaning of these 
findings. However, these results suggest areas that may be targeted by treatment interventions to 
reduce patient distress levels. Understanding patient perceptions may also have the potential to 
improve adherence to treatment regimes, recovery and quality of life as has been found in other 
illnesses (Petrie et al., 2007; Scharloo et al., 2005). 
 
Patients appeared to be moderately satisfied with information as a whole prior to treatment. They 
were most satisfied with information about their treatment and least satisfied with practical 
information relating to parking, transport and follow-up plans. This is probably because they had 
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not received this information prior to the education program. Patients who reported greater 
satisfaction with the explanation of their illness were least distressed. Although this finding is 
correlational it appears to be consistent with previous research on the effect of  information on 
distress (Fallowfield et al., 1995; Gamble, 1998).  
 
Patients reported higher levels of confidant support than affective support. That is, they felt they 
received more opportunities to talk to others about problems than love or affection. These 
finding are consistent with social support rated by early stage breast cancer patients (Trunzo & 
Pinto, 2003). It may be that patients have more access to confidant support because it can be 
provided by extended family and friends easily via telephone communication. However, 
affective support may be primarily provided by close family members who are likely to be 
occupied by many competing demands and perhaps their reaction to the patient’s illness and 
treatment and the life changes thereby imposed upon their own lives. In contrast to previous 
studies, we did not find a relationship between patient social support and psychopathology. The 
lack of associated may be because the majority of patients appeared to have high levels of social 
support. 
 
Levels of caregiver burden were high in our sample. Compared to carers of late palliative cancer 
patients, HSCT caregiver burden was significantly greater. Aside from family support (how easy 
it is to get support from family), significant differences were observed for the total score and the 
remainder of the subscales. Thus, caregivers perceived more burdens on self-esteem, finances, 
daily schedule and health. These results are consistent with Foxall & Gaston-Johansson’s study 
(1996) in which carers of HSCT patients reported fatigue, disruption to everyday life and 
financial strain as the major causes of burden. Although total burden was not related to any of 
the distress measures, greater burden on carer health was associated with higher levels of carer 
depression. Poorer carer health due to caregiving is likely to be a one of the most important 
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indications of carers who are struggling to cope. Thus, this may explain the association between 
health and depression, particularly since carers may include mental health in their responses to 
this factor. It is surprising that overall burden was not correlated with carer distress, as this has 
been observed in other caregiver samples (Grov et al., 2006). Research using different measures 
of burden may be useful in order to explore the relationship between burden and distress in 
HSCT carers more thoroughly. 
 
This study had a number of limitations. Firstly, the participants were a small sample of those 
who were invited to (and intended to) attend a HSCT education program. This study had a low 
recruitment rate and a limited number of constructs could be measured. Because of the small 
sample, we could not justify multivariate statistics, such as investigating predictors of distress 
through regression analysis due to power. Despite these limitations, this study is one of the first 
to investigate illness perceptions is HSCT and the relationships between illness perceptions and 
distress; and predictable relationships were observed. Furthermore, this is also one of the first 
studies to investigate carers’ distress and caregiver burden in HSCT and the results suggest these 
are important areas for future research. 
2.4.2. CONCLUSION 
This evaluation supports previous studies that have demonstrated that HSCT patients experience 
higher rates of anxiety and depression than do other oncology patients. A surprising and 
important finding is that most carers are experiencing even greater anxiety and distress than the 
patients. In line with this finding, levels of caregiver burden were found to be high and burden on 
health was related to higher levels of depression. More support is needed to facilitate coping and 
reduce rates of psychopathology in patients and carers early on in the process of HSCT. Because 
patient and carer psychopathology are associated with one another it is important to provide 
support for both patients and carers. Furthermore, patient distress is associated with a number of 
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illness perceptions that have been shown to affect recovery and quality of life post-HSCT. 
Therefore, it may be beneficial to provide patients with interventions that would influence 
helpful illness perceptions. 
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CHAPTER 3: RANDOMISED CONTROLLED TRIAL OF A 
PSYCHOEDUCATION PROGRAMME  
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3.1. INTRODUCTION 
Haematopoietic Stem Cell Transplantation (HSCT) is a medical treatment involving the 
transplantation of blood stem cells. Although previously considered a last resort procedure it is 
increasingly being used to treat patients with a range of diagnoses (Bone Marrow Transplant 
Network NSW, 2006). Some significant advances have been made in the use of HSCT. However, 
it is still considered to be a complex procedure that is arduous and associated with high-risk 
(Heinonen et al., 2005). Only 50% of patients with leukaemia who undergo HSCT are expected 
to be free of their primary disease 2 years after transplantation (Kulkarni et al., 2000).  
 
Patients and families are often under considerable stress due to the arduous nature of HSCT. 
Some of the psychological sequelae that patients undergoing HSCT experience include 
psychological distress, anxiety over loss of control, physical complaints, sexual dysfunction, 
problems with social relationships, occupational disability and financial consequences (Baker, 
1994). It has been suggested that patients undergoing HSCT would benefit from being informed 
about the side effects of treatment as it can help patients with decision-making and provide 
realistic ideas about what to expect after HSCT (Broers et al., 2000). To date however, there are 
no studies that have specifically addressed this issue in relation to HSCT. Similarly, there has 
been limited research on the educational needs and experiences of HSCT carers and families. The 
results in Chapter 2 have highlighted the fact that carers can be even more distressed than 
patients. Thus, there is a considerable need for empirical evidence evaluating education 
interventions for carers of HSCT patients. 
 
Patient education has generally been found to have a number of positive benefits for the patient  
in a range of illnesses, including cancer, rheumatoid arthritis and chronic obstructive pulmonary 
disease (Fernsler & Cannon, 1991). Education had been associated with improvements in 
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knowledge and recall, quality of life, decision-making, commitment to treatment, symptoms, 
symptom management, satisfaction, adaptation to illness, length of hospital stay, health care 
utilisation, post-operative opioid use and anxiety and depression (Fernsler & Cannon, 1991; 
McPherson et al., 2001; Treacy & Mayer, 2000; Yoon et al., 2006). In oncology specifically, 
patient education has been shown to increase knowledge and emotional functioning and 
satisfaction and reduce treatment problems, anxiety, depression and overall distress (Dodd, 1988; 
Gundel et al., 2003; McQuellon et al., 1998; Poroch, 1995; Treacy & Mayer, 2000). 
Retrospectively, HSCT patients have reported that having more information about HSCT before 
treatment would have helped to reduce distress and uncertainty (Rini et al., 2007). 
  
Not all education programs are associated with positive results. Cartledge and Haaga (2005) 
found no differences between the intervention and control group in anxiety, distress, treatment 
adherence or knowledge following an education program for radiation treatment. However, the 
intervention group were more satisfied with their care and were more likely to utilise 
psychological services. Hagerty and colleagues (2004) investigated the informational needs of 
126 patients with metastatic cancer. Patients who had a poorer prognosis were less likely to want 
to know how long they were expected to live. Likewise, a large survey of cancer patients 
revealed that patients who reported higher levels of anxiety and those with a worse prognosis had 
less desire for information (Kaplowitz et al., 2002). These results provide evidence that some 
people prefer not to be given information, particularly if they are anxious and/or have a poor 
prognosis. HSCT is associated with a poor prognosis compared to many other cancer treatments 
and, as the results of chapter two indicate, HSCT patients have high levels of anxiety. As such, it 
is not entirely clear whether the benefits of education found in other settings will generalise to 
HSCT. 
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Westmead Hospital in Sydney provides an intensive four-hour seminar for all patients and their 
families. The education program is held every two months and all patients who are listed to 
receive a transplant are invited. Generally the size of the groups are around 15-30 people 
including family members. The programme involves a series of presentations provided by 
members of the multidisciplinary team including a haematologist, transplant coordinator, clinical 
nurse consultant, transplant nurse, dentist, dietician, social worker and clinical psychologist (see 
Appendix A for presentation slides). A presentation is also given by a patient who survived 
HSCT about their experience before and after treatment. The intervention includes introductions 
of the primary staff members, background on HSCT, procedures required prior to admission and 
important contacts. Patients are also provided with information about pre-treatment and follow-
up procedures, important recovery time points, serious complications and side effects, hospital 
stay and infection control procedures. Other components of the education programme include 
psychosocial effects, oral hygiene, nutrition, and social and practical support. Many of the slides 
are accompanied by pictures, which aid comprehension, and some ‘hands on’ demonstrations are 
included to familiarise patients with central lines and masks/gowns. Patients and families are 
provided with slides to accompany the presentation. The seminar is interspersed with morning 
tea, lunch and afternoon tea, provided by the Cancer Council. During these breaks, patients and 
families have the opportunity to talk with staff. Following the programme, patients can visit and 
inspect the ward where they will be treated.   
 
Despite the support for education programmes in oncology, HSCT is a relatively rare procedure 
and has a considerably poorer prognosis than other cancer treatments. Thus, we cannot assume 
that education interventions are helpful in HSCT. The aim of this study is to provide the first 
evaluation of a patient education programme for patients undergoing HSCT and their carers. The 
questions that will be examined by this research are: (1) How effective is education for patients 
and carers? and (2) Is there a relationship between knowledge following the education 
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programme day and distress? It was hypothesised that education would lead to an overall 
increase in knowledge not evidenced in a group waiting to receive the education programme. It 
was also hypothesised that education would not increase patients’ anxiety and depressive 
symptoms, but rather that patients who knew more about their condition and its treatment would 
be the least distressed. 
3.2. METHOD 
3.2.1. PARTICIPANTS 
The participants were a consecutive sample of patients enrolled to have allogeneic or autologous 
HSCT at Westmead Hospital who were invited to attend the education program. Patients whose 
transplants were scheduled between education days or at the time of the education program were 
not able to attend. This was also true for patients who were sick at the time the program was held 
because it was unsafe for them to be around other people. Patients who were non-English 
speaking were excluded from the study. 
 
At the outset of the study, it was advised that at least 12 patients attended each education day. 
With 6 days held per year, it was estimated that we could expect a sample of 72 patients plus 
carers. Most patients who were invited to attend the education day over the course of the study 
were also asked to consent to be contacted about the research (see Appendix B for contact and 
consent forms). Some patients were not given the opportunity to consent to be contacted about 
the study because they were invited to attend the education program just prior to the day and 
hence too late to participate due to randomisation.  
 
Data was collected over a fifteen-month period between December 2006 and February 2008, 
which included eight education days. One hundred and two patients were invited to attend the 
education program over this period. Of these, 75 patients were invited to be contacted about this 
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research study. Forty-one patients replied to the transplant coordinator that they would not be 
able to attend the education program. Reasons for not attending were being too sick, in hospital, 
distance to travel, financial difficulties, being invited too late, and no longer being on the 
transplant list. Thirty-six agreed to be contacted about the research study. Only 51 patients 
actually attended the education program and 33 participated in the study. One patient who had 
agreed to be contacted had decided not to attend due to distance, one was excluded as they were 
non-English speaking, and the third was participating in another research project and felt it 
would be too much to do both. Attrition rates for three time points were 65% at pre, 59% at post 
and 39% at follow-up. 
3.2.2. PROCEDURE 
Patients were enrolled in the research up to 10 days prior to the next education day and stratified 
according to whether they are awaiting allogeneic or autologous HSCT. Randomisation to 
education or control group was conducted using SPSS Bernoulli function, which was concealed 
until after each consecutive patient had consented to participate. Patients nominated a primary 
carer and carers were allocated to groups by patient. Patients and carers were contacted by 
telephone to answer a battery of questionnaires, which took approximately 20 and 10 minutes 
respectively to complete. Those in the control group completed the questionnaires twice (one 
week apart) while waiting for the educational day. Those in the intervention group completed the 
same measures one week prior to the education day and immediately after. Both groups received 
the education program and were followed up at 100 days post-transplant. 100 days post 
transplantation is a commonly used time point that is used to access the success of the 
transplantation. Therefore, it was expected that we would see the most changes at this stage.  
However, because education is already offered as part of routine care, the waitlist needed to have 
the opportunity to attend the education programme in the meantime. 
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3.2.3. MEASURES 
Detailed information on all the measures and psychometrics are included in Chapter 2. See 
Appendix C for patient and carer questionnaires. 
Demographics Questionnaire 
A demographic questionnaire was used to obtain information on the participants’ age, marital 
status, number of children and ages, cultural background, illness, diagnosis, transplant type that 
was collected by patient report prior to treatment.  
Knowledge Questionnaire 
A knowledge questionnaire was developed based on the information in the education 
programme. Six experts in the field were consulted on what should be included. The final 
version of the questionnaire consisted of 20 items. Participants were asked to respond to each 
item on a 5-point Likert scale using true or false, probably true or probably false, or not sure. 
Chronbach’s alpha was used to examine internal consistency of the scale, which was 0.67 for 
patients and 0.50 for carers. A total knowledge score was created by reverse scoring items so that 
a higher score indicated greater knowledge. To be able to determine the level of improvement in 
knowledge a total mean score was used. The total knowledge score ranged from 1-5. 
Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) 
The HADS is a 14-item self-report screening measure designed to detect depressive and anxiety-
related symptomatology in medical patients. The depression and anxiety subscales were used to 
assess changes in patients and carers over time.  
Distress National Comprehensive Cancer Network Distress Thermometer (NCCN, 1999) 
The Distress Thermometer (DT) is a one-item screening tool for assessing distress in cancer 
patients. It asks patients to rate their level of distress over the past week based on the rating scale 
used to measure pain: 0 (no distress) to 10 (extreme distress).  
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3.2.4. PATIENT MEASURES 
Brief Illness Perception Questionnaire (BIPQ) (Broadbent et al., 2006) 
The BIPQ is a short nine-item scale designed for taking a quick assessment of cognitive and 
emotional perceptions of illness. Patients are asked to rate how much each item applies to them 
on a 10-point scale. The cause of illness item was left out of this study.  
Information Satisfaction Questionnaire (ISQ) (Thomas, Kaminski, Stanton, & Williams, 
2004) 
The ISQ was designed as an auditing tool for assessing the specific information concerns of 
cancer patients. The questionnaire includes one item assessing information needs on a 3-point 
scale, a yes/no item asking if information could have been improved and 6-items examining 
satisfaction with specific categories of information. For the purpose of the study, we only used 
the six items as they can be combined to create a total score. 
Duke-University of North Carolina Functional Social Support Questionnaire (FSSQ) 
(Broadhead et al., 1988) 
The Duke-UNC Functional Social Support Questionnaire is a brief 8-item self-report measure 
designed to assess a person’s satisfaction with functional and affective social support. It consists 
of two scales, Confidant Support (5 items) and Affective Support (3 items). This test has been 
shown to have good reliability but low convergent validity (McDowell, 2006). 
3.2.5. CARER MEASURES 
Caregiver Reaction Assessment (CRA) (Given et al., 1992) 
Consisting of 24-items, the CRA aims to assess caregiver experiences in five domains: daily 
schedule, the financial situation, relationships with others, physical health and self-esteem. The 
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CRA has been found to have sound psychometric properties when applied to carers of cancer 
patients (Nijboer et al., 1999). 
3.2.6. DATA ANALYSIS 
Baseline differences between the intervention and control group were assessed using parametric 
(for continuous variables) and non-parametric (for dichotomous variables) tests to identify 
covariates. A series of 2 (group: education; control) X 2 (time: pre; post) mixed model 
ANCOVAs were performed, using SPSS 15.0 for Windows, to determine the effectiveness of the 
intervention. Controlling for transplant type was considered because of the differences in risk 
between autologous and allogeneic transplants. However, we decided not to control for it 
because there were equal numbers of each transplant type in both groups and no significant 
relationships were found between transplant type and any of the other variables. Correlations 
were conducted to look at the relationship between knowledge following the education day and 
distress. Since all patients had received the intervention at follow-up it was only possible to 
assess what happened over time. Data was assessed using paired t-tests for baseline and follow-
up results. We also thought it would be worthwhile to see whether there were any significant 
relationships between survival and other measures. Spearman Rho correlations were used to 
analyse this data. 
3.3. RESULTS 
See Appendix D for data analyses. 
3.3.1. DEMOGRAPHICS 
Thirty-two patients and 30 carers consented to participate in the study. Two patients’ chose not 
to ask their carers to participate due to perceived burden on them and one carer participated 
without the patient due to the patient being non-English speaking. All sixty-two participants 
(100%) completed pre-treatment questionnaires. At post-treatment 30 patients and 30 carers 
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completed post-treatment measures (97%). One patient was hospitalized and was unable to 
complete the second telephone survey and another patient withdrew due to problems with the 
psychological aspect of the study. Twenty patients and 20 carers completed questionnaires at 100 
days post-transplant (65%). Five patients had passed away, three declined to participate, one had 
a brain infection and was unable to participate, and one was unable to be contacted. Attempts 
were made to contact the carers of the deceased patients. Only one of these carers was 
contactable and participated at follow up. Of the remaining six carers, three carers declined to 
participate and three were unable to be contacted. One patient and carer had separated following 
the transplantation but they both agreed to participate at follow-up. 
 
The mean age for the intervention group was 45.50 (S.D. = 12.25) and 48.19 (S.D. = 11.23) in 
the control group. In the education group, there were 9 male and 7 female patients and 7 male 
and 10 female carers. In the control group, there were 12 male and 4 female patients, and 4 male 
and 1 female carer. There were no significant differences between the intervention and control 
groups for patient age (t(1, 30) = -.65, p = .523) or gender (χ2= 1.25, p = .264). This was also the 
case for carer age (t(1, 29) = .46, p = .649) and gender (χ2 = .42, p = .519). Nor were there any 
significant differences for any other demographic or disease measures (see Appendix C).  Refer 
to Chapter two for more demographic details for the sample. 
3.3.2. KNOWLEDGE 
At post-treatment both patients and carers in the education groups showed improvement in 
knowledge compared to controls (see Table 10 for means and standard deviations). For patient 
knowledge, there was a main effect for time indicating that all patients, regardless of education 
became more knowledgeable over time (F(1,27) = 17.13; p < 0.000; η2 = 0.39). Importantly the 
group by time interaction was also significant indicating that those in the intervention group had 
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greater improvement in knowledgeable compared to the controls (F(2,27) = 29.26; p < 0.000; 
η2 = .31).  
Figure 1: Interaction of patient knowledge by group 
 
A time effect was also found for carer knowledge (F(1,27) = 12.31, p < 0.01, η2 = .25) with 
carers becoming more knowledgeable with time (see Table 11). As with patients, an interaction 
effect was found for carer knowledge such that carers in the education group became more 
knowledgeable than controls following education (F(2,27) = 9.17, p < 0.01, η2 = .25).  
Figure 2. Interaction of carer knowledge by group 
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3.3.3. PSYCHOPATHOLOGY 
There were no significant main or interaction effects of group on any of the psychopathology 
measures. Specifically the time by group interaction for depression was not significant for 
patients (F(2,28) = .592, p = .448, η2 = .21) or carers (F(2,27) = .239, p = .629, η2 = .008). This 
was also the case for anxiety, with no significant time by group interaction for patients 
(F(2,28) = .035, p = .852, η2 = .01) or carers (F(2,28) = .974; p = .332; η2 = .34). There was also 
no group by time effect for patient (F(2,28) = .159; p = .693, η2 = .124) or carer (F(2,28) = .133, 
p = .718, η2 = 0.005) distress. 
Table 11: Patient group means and standard deviations 
Group Means & (SDs) Education Control 
 Pre Post Pre Post 
Knowledge 3.88 (.46) 4.41 (.44) 4.21(.42) 4.14 (.45) 
Depression (HADS) 6.00 (4.69) 6.00 (5.36) 6.53 (3.38) 5.60(4.31) 
Anxiety (HADS) 6.80 (4.16) 6.80 (4.49) 7.60 (4.79) 7.73 (4.80) 
Distress (DT) 3.33 (2.44) 4.13 (3.18) 4.47 (2.45) 5.00 (1.77) 
Consequences 7.47 (2.10) 7.33 (2.35) 7.47 (2.10) 7.80 (1.61) 
Timeline 4.20 (2.60) 4.80 (2.04) 4.21 (3.24) 5.71 (2.61) 
Personal Control 2.73 (2.69) 3.47 (2.03) 3.00 (3.38) 3.93 (3.26) 
Treatment Control 8.73 (1.75) 8.00 (1.77) 9.00 (1.65) 9.20 (1.15) 
Identity 3.67 (3.09) 4.13 (2.85) 4.86 (2.93) 4.71 (3.22) 
Concern 8.20 (1.93) 7.33 (2.13) 9.00 (1.46) 8.33 (1.88) 
Understanding 7.27 (2.43) 7.73 (1.62) 8.27 (1.75) 7.73 (1.87) 
Emotion 6.13 (2.13) 5.87 (2.50) 6.80 (2.27) 6.07 (2.28) 
Information Satisfaction 2.69 (.56) 2.89 (.50) 2.96 (.56) 2.97 (.71) 
Confidant Support 20.17 (4.34) 11.36 (2.59) 22.07 (3.03) 12.44 (3.17) 
Affective Support 14.47 (.92) 13.33 (2.89) 14.53 (.92) 14.73 (.70) 
Table 12: Carer group means and standard deviations 
Group Means & (SDs) Education Control 
 Pre Post Pre Post 
Knowledge 3.80 (.34) 4.24 (.45) 4.09 (.50) 4.13 (.52) 
Depression (HADS) 6.50 (3.60) 6.63 (3.84) 6.86 (4.80) 7.36 (5.05) 
Anxiety (HADS) 10.00 (4.15) 10.00 (4.27) 10.07 (4.46) 10.93 (4.39) 
Distress (DT 5.31 (1.89) 5.50 (2.73) 5.21 (2.52) 5.14 (2.44) 
Caregiver Burden 15.13 (2.30) 14.71 (1.76) 15.48 (1.55) 15.18 (1.71) 
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3.3.4. OTHER MEASURES 
No significant interaction effects were found for group by time on any of the illness perceptions 
items (see Table 12). A significant time effect was found for Timeline (F(1,27) = 7.624, p = 
.010, η2 = .22) such that patients’ perception of how long their illness would continue increased 
with time regardless of intervention. There was no difference for patient information satisfaction 
with education (F(2,28) = 1.02, p = .321, η2 = .04). On the social support measure, there was a 
significant time effect for confidant support (F(1,28) = 194.05, p < 0.000, η2 = 0.87). All 
patients reported less confidant support over time. There were no significant main or interaction 
effects for either confidant support (F(2,28) = .38, p = .540, η2 = 0.14), affective support 
(F(2,28) = 2.66; p = .114; η2 = .09) or caregiver burden (F(2,28) = .14, p = .715, η2 = .01). 
Table 13: Group by time effects for illness perceptions 
 df T-Score Sig. (2-tailed) η2 
Consequences 28 .39 .537 .01 
Timeline 27 1.40 .247 .05 
Personal Control 28 .03 .861 .00 
Treatment Control 28 2.50 .125 .82 
Identity 27 .38 .545 .01 
Concern 28 .05 .824 .00 
Understanding 28 2.25 .145 .07 
Emotional Response 28 .66 .425 .023 
3.3.5. CORRELATIONS 
Correlations between patient and carer knowledge post-education and distress measures are 
shown in Table 13.  
Table 14: Correlations between knowledge and distress measures 
Correlations Patient 
DT  
Patient 
Anxiety 
Patient 
Depression 
Carer 
DT 
Carer 
Anxiety 
Carer Depression 
Patient 
Knowledge 
-.378* -.011 -.243 .135 .310 .056 
Carer Knowledge -.306 .044 -.266 -.329 -.167 -.302 
*  Correlation is significant at the 0.05 level (2-tailed). 
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The only significant correlation was between patient knowledge at post-education and patient 
distress. Greater knowledge post-education was associated with less distress on the DT.  
3.3.6. FOLLOW UP 
Significant differences were found at 100-day follow-up for patient and carer knowledge and 
carer anxiety (see Table 14). Patients and carers had higher knowledge scores at follow-up 
compared to baseline. Carer anxiety had reduced significantly at follow-up, with the mean score 
close to the normal range. Differences were also found for consequences and concern on the 
BIPQ. Patients perceived the illness as have less effect on their life (Consequences) and were 
less concerned about their illness at follow-up. Affective and confidant support also showed 
significant change at follow-up. Patients reported having more affective support but less 
confidant support at follow-up versus baseline. 
 
Table 15: Significant differences at follow-up 
 Baseline Follow-up T-Score Sig. (2-tailed) 
Patient Knowledge 81.25 (9.27) 86.00 (8.32) -2.767 .012 
Carer Knowledge 80.70 (7.87) 87.85 (5.31) -5.244 .000 
Carer anxiety 9.80 (4.47) 7.65 (3.59) 2.772 .012 
Consequences 7.58 (2.19) 6.11 (2.51) 2.220 .040 
Concern 8.79 (1.36) 6.42 (2.39) 4.415 .000 
Affective 14.50 (.52) 14.83 (.71) -2.062 .055 
Confidant 20.75 (3.89) 11.83 (3.23) 9.230 .000 
3.3.7. SURVIVAL 
At 100-day follow-up, 15% (N = 5) of patients had died. All of the patients who had died had 
received allogeneic transplants. Infection (N= 4) and acute GvHD (N = 1) were the causes of 
early death in this sample. There were no significant relationships between survival and illness or 
demographic variables. There was a correlation between personal control and survival post-
education (r(30) = -.48, p = .007). Lower perception of personal control post-education was 
associated with mortality.  
  79
3.4. DISCUSSION AND CONCLUSION 
3.4.1. DISCUSSION 
The aim of the present study was to evaluate the effectiveness of an education intervention for 
HSCT patients and carers. We were also interested in examining the effect of education on 
distress and whether there was a relationship between knowledge following the education 
programme and distress. It was hypothesised that education would lead to increased patient and 
carer knowledge compared to waitlist controls. In addition, we predicted that the education 
programme would not have adverse effects on anxiety and depressive symptoms and that those 
who knew more about HSCT would be the least distressed.  
 
The intervention was successful in achieving its primary goal of increasing knowledge. Patients 
in the education group showed increased knowledge about HSCT compared to patients in the 
control group. This was also true for their carers. Looking at the means on the knowledge scale, 
on average both patients and carers appeared to have a reasonable understanding to begin with 
but they became more certain following the education programme. Importantly, the education 
programme did not have any adverse psychological effects for either patients or carers. There 
were no differences between the groups in terms of depression, anxiety, or distress. We expected 
that the education programme might result in decreases in distress. However, this was not the 
case. There was, however, a significant correlation between patient knowledge following the 
education programme and distress. Consistent with the hypothesis, greater knowledge was 
associated with less distress. 
 
There were also no differences between the groups in terms of patient illness perceptions, patient 
information, patient social support or caregiver burden. However, changes over time were found 
for the BIPQ timeline scale and confidant social support. Patients’ perception of how long their 
  80
illness would continue increased with time and they reported decreased confidant support with 
time. As time progresses, it is not unusual that patients would have a better understanding of 
their illness and the fact that it will take a long period of time to be well again. This is 
particularly true for HSCT patients because in some cases they will never be considered 
completely ‘cured’. The finding that perceived confidant support decreased with time may be a 
result of important support people in the patients’ life simply being less available or having less 
capacity to be as personally accessible. Alternatively, patients may perceive their need to confide 
in others as a burden to their support people. Further research is needed to explain this finding.  
 
Patients and carers were followed up at 100 days post transplant in an attempt to evaluate the 
long-term impact of the education programme. At 100-day follow-up, patients and carers’ 
knowledge was still significantly greater than baseline. Patients perceived fewer consequences 
from, and had less concern about, their illness. They also felt they had more affective, but less 
confidant, support compared to baseline. There were no changes in patient anxiety or depression, 
but carer anxiety decreased over time; with the mean score at 100 days post-transplant falling 
within the normal range. It is heartening that carer anxiety improves with time and indicates that, 
even without support, carers will be able to cope despite high levels of anxiety. Unfortunately, 
due to the importance of all patients and carers receiving education it was not possible to 
randomize this aspect of the study. Hence, it is unclear whether changes can be attributed to the 
education programme. Although this study is unable to conclude any long-term benefits in 
relation to the education programme, it is possible that there are positive long-term effects on 
carer anxiety. It is a concern that there were no reductions in patient distress. The findings that 
patients’ perception of the impact of their illness and concern for their illness decreased over 
time is, however, positive. This finding highlights the significance of the 100-day time point as a 
marker of hope for patients. This may also indicate the possibility that reductions in 
psychological symptomatology would be observed in patients over the longer-term, such as six 
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months to one year. An interesting association was found for perceived personal control and 
survival post-education. Lower perceived control over one’s illness was significantly correlated 
with mortality. Perhaps this finding relates to helplessness or patients who are less well 
accurately perceive that they have less personal control over the outcome.  
 
Although steps were taken to minimize limitations with the methodology, there are nevertheless 
areas for improvement in this study. Despite a long period of recruitment, there was a 
significantly lower recruitment rate than was anticipated. Recruitment was affected in part due to 
the attendance of the education programme itself. Approximately 50% of patients declined the 
offer to receive education. Many patients lived a long distance from the transplant hospital and 
they may have found it difficult to attend. Other patients may have decided they did not want 
more knowledge. Attempts were made to minimize burden from the study on participants, 
however some patients may have still decided not to participate due to the perception of the 
study creating even greater burden. Other patients were unable to participate because they were 
only invited to the education programme just prior to the day of its occurrence; making it 
impossible to randomize and assess them in time. The psychological aspect of the study as well 
as the invitation to carers could have also discouraged some patients from participating. The fact 
that such a large proportion of patients declined to attend the education programme also raises 
questions about the generalisability of the results. Finally, the small sample size is problematic 
because it affects power, reducing the number of constructs that could be examined and 
preventing the use of multivariate statistics.  
 
It would have been interesting to look at the effect of the two types of transplant on participants’ 
experience of the education programme. Because HSCT is so rare, in practice education 
programmes typically combine patients receiving allogeneic and autologous HSCT. Having a 
combined information day for autologous and allogeneic HSCT patients may result in decreased 
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anxiety for the low risk group (autologous) but increased anxiety for the high-risk group 
(allogeneic). On the other hand, it is equally possible that patients awaiting autologous 
transplants will not distinguish between the information that is relevant to them and the 
information relevant to patients awaiting allogeneic HSCT. This may inadvertently increase 
anxiety in the low risk (autologous) group. Additional information has been suggested to 
increase anxiety, especially when it is confusing or misunderstood (de Haes, 2006). 
Unfortunately, this study did not have the power to explore this aspect of the education 
programme but it would be useful for future studies to evaluate.  There was no indication of 
these affects in the small sample in this study. 
 
These limitations notwithstanding, this study also has a number of strengths. It was the first 
evaluation of the effects of a patient education programme for HSCT patients and carers and one 
of the few to include both allogeneic and autologous transplant types. The evaluation 
demonstrated that the educational intervention was effective in increasing knowledge and 
importantly, greater knowledge did not increase patient or carer distress. 
3.4.2. CONCLUSION 
This was the first randomized study evaluating a patient education programme for patients 
undergoing HSCT and their carers. Patients and carers experienced an increase in their 
knowledge of HSCT as a result of the education programme. This knowledge did not adversely 
affect patients or carers in terms of anxiety or depression. Rather patients with more knowledge 
were found to be least distressed. The education programme did not have any effect on 
information satisfaction, illness perceptions, social support or caregiver burden. Patients and 
carers knowledge was still significantly greater than baseline at 100-day follow-up. Patients also 
perceived fewer consequences from, and had less concern about, their illness. They also felt they 
had more affective but less confidant support compared to baseline. Carer anxiety returned to 
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within normal levels for anxiety, but depression did not change. Furthermore, there were no 
changes in patient symptomatology. These findings support the use of an education programme 
for increasing knowledge without affecting patient and carer distress. There is also a need 
demonstrated, however, for greater psychosocial supports for both carers and patients.  
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CHAPTER 4: GENERAL DISCUSSION 
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4.1. MAJOR FINDINGS 
This primary purpose of this investigation was to run the first randomised controlled trial of a 
patient education programme for patients undergoing HSCT and their carers. This objective 
raised the following questions: (1) what are the rates and correlates of distress in HSCT patients 
and carers, (2) what effect does education have on patients and carers and (3) is there a 
relationship between knowledge following the education programme and distress? Based on the 
existing literature evaluating the effect of education on patients with cancer and other serious 
illnesses, it was hypothesised that education would lead to an overall increase in knowledge, not 
evidenced in a group waiting to receive the educational programme. It was also predicted that 
increasing knowledge would not increase patient or carer anxiety or depressive symptoms. 
Furthermore, it was hypothesised that patients who knew more about their condition would be 
the least distressed. 
 
High rates of psychopathology were found for patients and carers. Approximately forty percent 
of the patient sample had depressive symptomatology in the clinical range. This was also 
supported by patient ratings of distress, with 40% reporting clinical levels. The presence of 
clinically significant anxiety was even greater with about half the patient sample indicating high 
levels of anxious symptomatology. There were no differences between patients and carers in 
terms of depression, with a similar number of carers reporting clinically depressive 
symptomatology. However, there was a significant difference between patient and carer rates of 
anxiety and distress. On both measures, 70% of carers reported symptoms of anxiety and distress 
indicative of a need for clinical support. This is an important finding because rates of clinically 
significant symptoms in carers of HSCT patients have not received as much attention as the 
patients. Thus, it has not necessarily been assumed that carers could require more psychosocial 
support than patients. 
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The primary goal of the intervention programme is to provide patients with more information. 
The results provide support for the effectiveness of the psychoeducation programme, as there 
was a robust increase in both patient and carer knowledge. Patients in the education group had 
significantly greater knowledge compared to controls. This was also true for carers in the 
education group. Thus, the education programme is an effective intervention for providing 
patients and carers with greater knowledge and new information. At follow-up, there were also 
significant differences in patient and carer knowledge compared to baseline. Although, this 
cannot be attributed to the education programme, it is indicative that patients have maintained a 
higher degree of knowledge than they had prior to treatment. You would also expect that 
knowledge would increase by experiencing the procedure first hand. 
 
The hypothesis that would not be adversely affected by the education programme was support. 
Increasing knowledge did not lead to increases in anxiety and depressive symptomatology. The 
fact that the intervention does not appear to have any adverse effects whilst still providing 
patients and carers with more information lends further support to the effectiveness of the 
intervention. Interestingly, education did not lead to any reductions in patient or carer distress. 
This finding is contrary to research looking at the effect of education in other illnesses, including 
cancer, where patient education programmes have been useful in increasing knowledge and 
decreasing patient distress. Nonetheless, those who knew most about their illness following 
education were the least distressed. Hence, it is possible to exclude the possibility that 
information increases distress in any way. 
4.2. LIMITATIONS 
4.2.1. SAMPLE SIZE 
There were a few obvious limitations to this study. Firstly, the size of the sample was much 
smaller than anticipated. Originally, we aimed to get a sample of seventy-five patients in order to 
  87
have enough power to look at the differences between autologous and allogeneic transplant types 
with education. Over the sixteen months of data collection, which included eight education 
programmes, 102 patients were invited to attend education. Seventy-five of these patients were 
invited to be contacted about the study. Only 36 out of these 75 patients consented to be 
contacted by the researcher about the study. While this might give an indication of a very low 
recruitment rate, only 51 (50%) of the original one hundred and two patients actually took up the 
offer to receive education. Those who did not attend would have been ineligible to take part in 
any case. Thus only 51 patients were potential participants for this study. Of these, we were able 
to recruit 32 patients (63%) of those who actually attended the education programme. Further, 
out of the 36 who elected to be contacted, a very high proportion agreed to take part in the study 
(32/36). Of those who declined, one was excluded due to being non-English speaking, two had 
decided not to attend the education programme due to travel distance and the fourth was 
participating in another research study already and did not want to be over burdened.  
 
Therefore, although the education programme was helpful for those patients who did attend, a 
high proportion of patients chose not to receive education. This raises issues about whether those 
who attend the education programme have different information needs compared to those who 
do not attend. A considerable number of patients came from regional NSW and faced difficulties 
with travel costs and accommodation in order to attend the education programme. For example, 
one of the patients who declined to attend due to travel lived close to the Queensland border. He 
said that they could not afford to travel for the education programme because they would need to 
travel for the transplant itself and the cost physically and financially would be too great to do 
both. Therefore, it possible that rural patients are under-represented in the sample, although 
many of the participants were from regional areas. It is also possible that the people who chose 
not to attend differed systematically from those who attended. For example, it is possible that 
some people prefer not to receive information. The low take-up rate for the education program 
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raises a dilemma. While it is not possible to force patients to attend or even to devise an 
education programme for those who do not want to be educated, it is quite concerning that such a 
large number of patients may be agreeing to HSCT in the absence of a proper understanding of 
the risks. The fact that this programme has been created in the first place indicates that it is 
important for patients to be educated about HSCT. Yet, almost half of all patients are not 
utilising this service.  
 
This is surprising given the research suggests that cancer patients generally want to receive 
substantial information about their illness and treatment. However, this finding concurs with 
some research that has found that cancer patients with higher levels of anxiety and worse 
prognosis have less desire for information (Kaplowitz et al., 2002). Certainly, there are 
individual differences when it comes to how much people want to know about conditions that 
may be threatening and confronting. While some people want to have all the information 
available, others are content to know the minimum required. A lot of research has been 
conducted on differences in patient information preferences. Although it is not within the scope 
of this thesis to explore this topic, it would be interesting for future research to investigate 
information preferences and associated behaviour in relation to HSCT. It may be necessary to 
encourage and better facilitate more comprehensive participation in the education programme, 
for example by providing an interactive Internet based education programme for remote patients, 
if the program is considered to be important for informed consent. This will at least provide the 
opportunity for all patients who are willing to be educated to receive the intervention. 
 
The psychological aspect of the study may have also discouraged patients from participating. 
One couple (patient and carer) withdrew from the study after time one because they were 
uncomfortable with the questions on the HADS. They felt that an investigation of their 
psychological functioning was unnecessary and unhelpful. Although only one patient and carer 
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in the sample reported feeling this way, there may have been others who chose not to participate 
in the first place in order to protect themselves from thinking about these aspects. Two patients 
did not take up the offer for the researcher to speak to their carer because they thought that their 
carers would not cope with being a part of the study on top of coping with the illness and 
treatment. Thus, patients and carers who chose not to be contacted may also have been protecting 
each other in this way. The fact that carers were asked to participate may have been enough to 
discourage some patients from participating themselves as they may have thought that they could 
not participate alone. Although these issues are speculative, it is possible that the people who 
chose to attend the education programme are different from those who declined to attend. This 
may limit the generalisability of the results. 
 
A major challenge to recruitment was the ethical requirement that the researchers were not able 
to contact patients directly. The Transplant Coordinator for the Bone Marrow Transplant ward at 
Westmead Hospital was initially only allowed to send out a ‘Permission to Be Contacted about 
Research’ form with a reply paid envelope along with the invitation to receive education. 
Following low recruitment to the study, the ethics committee allowed the Transplant Coordinator 
to also ask patients directly if they would be willing to be contacted (either in person or over the 
phone) because many people were missing out on taking part because they were being invited to 
the education day too late. Alternatively, it seemed that consenting to be contacted by the 
researcher over the phone to the Transplant Coordinator was much less a burden to patients 
compared to considering, completing and sending back a form. This change did improve 
recruitment to some degree because it at least meant that there were less patients missing out due 
to the late scheduling of the education programme. Some patients, however, were still not asked 
in time due to the need for randomisation in the study that required that the researcher contact 
participants a week prior to the education programme. Further, being contacted by the researcher 
who can explain the commitments of the study and the right to withdraw, is a different 
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experience for the potential participant than to have someone outside the study seek to explain 
what is involved. More patients may have taken part in the study if a different method of 
recruitment had been acceptable to the ethics committee.  
 
The small sample size presents a limitation in respect of power in the study. The effect of the 
sample size on power may have meant that some findings did not reach significance, but 
differences actually existed. However, an examination of the effect sizes (η2) suggests that the 
only two variables where power was likely to be an issue were (a) affective support; and (b) 
understanding. Both of these large effect sizes suggest that a difference would have been 
observed if 26 patients had been included in the sample. In addition to the issues of power, it is 
of note that there was no attempt to control for multiple comparisons by using a more stringent 
criteria. If we had adjusted for the 15 outcome variables, we should have adopted a stringent 
alpha value of 0.003. It was decided not to do so because this would have compounded the 
problem of power. Nonetheless, had a more stringent alpha level been adopted, the results would 
have remained largely unchanged as the major finding on knowledge was p < 0.003. 
4.2.2. LACK OF LONG-TERM CONTROLS  
While patients and carers were followed up, it was not possible to assess the effect of the 
education over time. In the unit at Westmead, the education programme was offered as part of 
routine treatment. There is no evidence that education is beneficial and therefore at one level 
there should not be any ethical objection to randomising patients. On the other hand, it is not 
considered ethical to withhold something considered part of routine treatment. This ethical 
constraint means, however, that the long-term outcome of education cannot be assessed. If it 
were possible to survey the patients who did not take up the offer to attend the education 
programme, it would be possible to compare them to the patients in our sample at follow-up. If 
the samples are systematically different, however, the comparison may not be valid. In hindsight, 
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given the large percentage of those who failed to attend, a more natural design of following up 
attendees versus non-attendees may have been preferred. Although one could have been less 
confident that differences were solely attributed to the education, such a design would have 
allowed other questions to be answered more clearly. Specifically, the differences between those 
who attended versus those who did not and the long-term effect of education would have been 
easier to gauge. This approach would also have allowed a larger sample for the analyses in 
second study. 
4.2.3. MEASURES 
Another shortcoming of the study was the limit to the type and number of measures that could be 
used. In designing the study, we were conscious of overburdening these very ill patients and we 
did not want the study to impact greatly on their time and effort. We also expected this would 
increase recruitment. Some measures were selected in preference to others because they were 
brief. In doing this, it is possible that we missed out on using measures which have stronger 
reliability and validity. For example, the Brief Illness Perception Questionnaire was selected 
over the more widely used and validated Illness Perception Questionnaire Revised (IPQ-R). The 
IPQ-R has been used to assess illness perceptions in breast cancer patients (Fotios & Efrosyni, 
2005). It is possible that we would have found more information if we had been able to use this 
longer measure. This was also the case for the measure of information satisfaction, social support 
and caregiver burden.   
4.2.4. TRANSPLANT TYPE 
This study also differed from other research on this patient population in that it looked at people 
having both autologous and allogeneic transplants. Most studies tend to look at just one type of 
transplant. Since initially we intended to examine the differences between these two groups with 
education, patients were equally randomised by transplant type. Unfortunately, due to limited 
numbers, there was not the power to evaluate this possible difference. Because there were equal 
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numbers of each transplant type in both groups and no indication of transplant type being 
correlated with any significant variables, we decided not to control for transplant type. However, 
it is still possible that transplant type could have an effect on the results. For example, we 
initially wondered whether those autologous patients with a better prognosis may be confronted 
by reference to complications, such as GvHD, which are not relevant to them. If autologous 
patients failed to distinguish between the information relevant to them versus that relevant to 
allogeneic patients, they may believe that their prognosis is worse than they thought. This would 
lead to increases in patient beliefs and possibly indices of distress. The opposite could be true of 
allogeneic patients. That is, they might think their prognosis is better as a result of taking on 
board information relevant to autologous patients, resulting in a decrease in distress and 
perceived seriousness of the condition. The fact that the education had different effects on the 
two groups may obscure any effects of the education. Although one would expect a correlation 
between transplant type and outcomes if this were the case, this possibility cannot be excluded. 
Therefore, it is a limitation of the study. On the other hand, because other studies have generally 
not included both autologous and allogeneic, there may be some benefit in looking at both 
groups together. 
4.2.5. INTERVENTION 
A further downside of the study was that it is not clear what it was about the particular education 
that was effective in improving knowledge. Patients are provided with written, verbal and visual 
information in the course of the education programme. The impact of having the 
multidisciplinary team invest time may have been important for patients. In addition, for each 
programme, a past patient is present to discuss their experiences and this experienced-patient to 
novice-patient may be very effective. There was no scale that measured participants’ response to 
the education programme.  Qualitative research is needed to assess patients’ reflections 
following the education programme in more detail. For instance, patients and carers commented 
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on the helpfulness of being able to meet the Transplant Coordinator at the education programme 
as they had only spoken to her on the phone previously. Also anecdotally, the presentation by the 
experienced-patient who had survived HSCT appeared to have a substantial and positive impact 
on the outlook of patients and carers alike.  
4.3. STRENGTHS 
Despite the aforementioned limitations of the study, this research has a number of strengths. 
Firstly, we were able to support the existing literature in terms of the higher proportion of 
clinically significant psychopathology in HSCT patients. More importantly, this study has 
brought to attention the substantial level of distress experienced by HSCT carers. Some 
preliminary investigation of illness perceptions were also conducted which showed relationships 
with distress. Finally, this was the first empirical evaluation of an education programme for 
HSCT patients and their carers and it found support for the intervention in increasing the primary 
outcome variable of knowledge without leading to detrimental effects on psychopathology. 
4.4. DISCUSSION OF RESULTS 
4.4.1. PATIENT AND CARER DISTRESS 
The rates of clinically significant distress were high in our patient sample with approximately 
50% of patients meeting the cut-off point of eight or above on the anxiety subscale of the HADS 
and almost 40% on the depression subscale. On the DT, approximately 35% met the cut-off score 
of five or above. In cancer generally, about a third of patients have been found to have significant 
distress (Zabora et al., 2001). Our results appear to correspond with the research on HSCT 
patients which have found the rates of distress to be higher than in other oncology settings. Trask 
et al (2002), examined rates of distress, anxiety and depression on the DT and the HADS in a 
sample of 50 candidates for HSCT. They found that 50% of the patients reported clinical levels 
of distress and 51% of patients reported clinical levels of anxiety. Less than 20% of the patients 
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reported clinically significant depressive symptomatology. We found a similar level of anxiety in 
our patient sample (48.4%). Levels of depression, however, were higher (38.7%) and less 
patients reported clinical levels of distress (34.4%). Leigh, Wilson, Burns and Clark (1995) 
found rates of abnormal psychopathology in 54% of patients before and after treatment with 
HSCT. Six to nine months later, patients still rated highly on psychological distress. 
Furthermore, Keogh and colleagues (1998) found moderate to high levels of anxiety and 
depression in 61% and 14% of patients respectively pre-treatment. Sixteen percent of prospective 
HSCT patients met criteria for major depressive disorder (Jenkins et al., 1994) and 28% of 
patients who had received HSCT described symptoms from the pre-treatment indicative of a 
major depressive episode (Jenkins et al., 1991). The results of this research are generally 
consistent with the literature. That is, HSCT patients have a high level of distress, anxiety and 
depression indicating a need for psychosocial support. 
 
The rates of distress in carers of HSCT patients have not received as much attention by 
researchers. In our sample, 70% of carers reported rates of anxiety and distress that were 
indicative of a need for clinical intervention and 40% reported clinical levels of depression. 
Keogh et al (1998) found 88% of HSCT relatives scored above the stress threshold on the GHQ 
pre-transplant. Sixty-two percent were still distressed at three months, 40% at six months, and 
18% at twelve months. Another study found carers of HSCT patients had  moderate levels of 
anxiety on the State Trait Anxiety Inventory (STAI) but normal levels of depression (Foxall & 
Gaston-Johansson, 1996). Foxall and Gaston-Johansson (1996) also found reductions in 
caregiver anxiety over time, with the lead up to HSCT being a time of increased anxiety 
compared to days 5 or 20 post HSCT. The results confirmed the very high rates of 
psychopathology in carers. Surprisingly, even higher levels of distress than those previously 
described for patients. This is an important finding because it means that carers are clearly 
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strongly affected by their role and the patient’s illness. Therefore, there is a vital need for 
psychosocial support for carers themselves. 
 
It is known that carers of HSCT patients experience major role changes and high levels of stress 
caring for these sick patients, with whom they are most often in close domestic relationships, 
over the long-term. Most of the carers in our sample were spouses, who also had children to care 
for, some of whom were dependents under eighteen years of age. Some carers in the sample 
were continuing to work as well as care or had recently taken up employment due to the patients’ 
loss of income. Some carers also mentioned the stress of not being able to talk to anyone about 
their fears for the future and the uncertainty about what would happen to their family. Some 
carers retrospectively spoke about the times when patients were very sick and they could not be 
near them for fear of spreading infection. There is the rule that children are not able to be on the 
ward and so they may only talk to their parent on the phone. One carer reported that at one stage 
her husband had such significant GvHD that he was not able to eat or talk due to severe mucitis, 
so their children would just speak to him on the phone and he would listen.  
 
Carer levels of anxiety did appear to decrease over time in our study; which is positive. 
Nevertheless, the mean level of anxiety in carers was still high at follow-up; indicating moderate 
levels of anxiety. The fact that the education programme is not sufficient to reduce anxiety in the 
short-term lends further support for the introduction of more targeted carer support intervention.  
4.4.2. CORRELATES OF PATIENT DISTRESS 
Correlates of patient distress were investigated in order to identify factors that may help 
differentiate patients who are likely to experience more significant psychopathology. A number 
of interesting relationships were found between patient distress and illness perceptions. The 
impact of illness and symptoms was associated with higher levels of depression. Not 
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surprisingly, depression, anxiety and distress were associated with perceiving greater emotional 
impact of the illness. Patients who were more anxious were more likely to perceive their illness 
continuing for longer and to have greater concern about their illness. Patients who reported 
greater satisfaction with the explanation of their illness were least distressed. Although this 
finding is correlational, it appears to be consistent with previous research on the effect of  
information on distress (Fallowfield et al., 1995; Gamble, 1998). No significant relationships 
were found for patient social support and psychopathology. More research is needed to 
understand the meaning of these findings since they are correlational. 
4.4.3. EFFECTS OF EDUCATION  
The results for knowledge showed that education did increase patient and carer knowledge about 
HSCT. This occurred despite the fact that many patients and carers had a reasonable level of 
knowledge prior to attending. A high proportion of patients and carers mentioned reading the 
book provided by the hospital, with some reporting too little information and others too much 
information. Many patients had received personal information from their specialist, the 
transplant coordinator or had acquired it from their own Internet research (e.g. The Cancer 
Counsel website). The data shows that patient and carer knowledge was high prior to treatment 
and that they became more accurate with the education. For patients, the degree of improvement 
was 3.88 to 4.41 out of 5. For carers it improved from 3.80 to 4.24 out of 5. This indicates that 
patients and carers were fairly correct and knowledgeable before education but became more 
certain afterwards. Patients who received the intervention had still greater knowledge post 
education. Knowledge was greater at follow up compared to baseline for patients and carers; 
indicating some level of retention over time. The primary aim of the education intervention was 
to provide information and therefore the programme is successful in fulfilling its primary 
purpose; and even in a previously well-informed patient group. 
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Our results concur with research on education programmes for oncology and other illnesses in 
terms of increasing knowledge (Fernsler & Cannon, 1991; McPherson et al., 2001; Treacy & 
Mayer, 2000; Yoon et al., 2006). However, education programmes have generally been found to 
provide other benefits apart from improving knowledge. Research on the positive effects of 
education have demonstrated reductions in psychopathology, increased participation in decision-
making, better commitment to treatment, improved symptom management, greater satisfaction, 
increased ability to cope, decreased hospital stay, greater health care utilisation, less post-
operative opioid use,  better symptom improvement and increased quality of life (Fernsler & 
Cannon, 1991; McPherson et al., 2001; Treacy & Mayer, 2000; Yoon et al., 2006). It was 
hypothesised that education would lead to similar changes in HSCT patients, but this was not the 
case. Despite the small sample size, it does not appear that this education programme would 
produce changes in many of our outcome measures in a larger sample based on the effect sizes. 
Hence, it seems these broader benefits were not forthcoming. 
 
Aside from knowledge, patient and carer distress was the most important outcome variable 
examined in this study because lack of information has been associated with increased anxiety 
and distress in cancer patients (Fallowfield et al., 1995). Indeed, that relationship was replicated 
in this study. That is, those patients with more knowledge had less distress. Furthermore, one of 
the main aims of education is often to alleviate helplessness and improve adaption to illness 
(Fawzy et al., 1995). Although there have been no randomised control trials examining the effect 
of education in HSCT, it has been reported by some of these patients that they would have liked 
to have more information about what to expect prior to treatment as this would have helped to 
reduce anxiety (Rini et al., 2007). Yet, because of the greater risks associated with HSCT it was 
also considered that education could have the opposite impact and increase distress.  
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The fact that patients and carers’ levels of distress did not change despite attending the education 
intervention is interesting to consider. Reflecting on the literature, a comparable randomised 
controlled trial of patients having radiation therapy also found no differences between the control 
and intervention groups for anxiety and distress (Cartledge & Haaga, 2005). While this is the 
case, it should be noted that these authors did not find any improvement in patient knowledge; 
which may explain their results. This was not the case in the present study. However, it is worth 
mentioning that levels of knowledge were high to begin with in our patient sample. The measure 
that we used to assess knowledge combined certainty and knowledge. The majority of patients 
knew most facts about HSCT prior to education but what increased was certainty. It may be 
because patients were well-informed at the outset that the increases in knowledge, while 
statistically significant, were not sufficient to change views or impact distress. 
 
Most studies of cancer patients have indicated that patients prefer to receive as much information 
as possible. The research suggests oncology patients want detailed information about diagnosis, 
treatment, side effects, symptoms and self-care needs (Hagerty et al., 2004; Treacy & Mayer, 
2000). Cancer patients have reported feeling dissatisfied with the quality and quantity of 
information that they have been given about their illness and treatment. Patients with cancer have 
also reported that they preferred to receive all the information possible about their disease and 
treatment regardless of whether it was good or bad (Blanchard et al., 1988). Furthermore, 
dissatisfaction with information provision about treatment and related risks has been found to be 
associated with increased anxiety, uncertainty, dissatisfaction, distress and poor treatment 
decisions in oncology patients (Fallowfield et al., 1995; Gamble, 1998).  
 
One of the reasons that the education intervention programme did not affect other outcome 
measures may be due in part to differences in individual reactions to the education programme 
day. Some people may have been reassured by hearing how the staff will look after them. For 
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many partcipants, where the patient had been previously treated in a hospital outside of Sydney, 
the education programme day was the first time they had met key staff (the transplant 
coordinator, nurses, the social worker, clinical psychologist, dentist and dietician). Some patients 
may have assumed that they were likely to die and meeting the team and hearing from the 
experienced patient who survived may have provided hope of survival and been otherwise 
reassuring. For others, the enormity and significance of the treatment could be made real by 
attending an education programme with their family. Prior to this, they may have been able to 
deny the reality of their predicament and avoided receiving more information. The impact of 
having the multidisciplinary team present an education programme of this type could be very 
comforting. On the other hand, patients could interpret the provision of the education as a need 
to cover the hospital and doctors in terms of informed consent, raising their awareness of the 
riskiness of the procedure.  Another factor is that specialists will have given patients a lot of 
information about their prognosis already. Having attended a number of the education 
programmes it was observed that patients commonly enquired about the risk of mortality when 
the specialist presenting asked for questions. A standard reply was that prognosis varied 
considerably depending on individual factors such as disease and age and that it was important 
that they talk to their specialist to receive a personal answer to that question. Finally, the 
education programme may not be providing all that patients and carers really need to help them 
cope. For instance, many patients particularly appreciated hearing from the experienced patient 
who had survived. However, this patient was not able to attend all the education programmes 
evaluated in the study and perhaps this affected the results. Reports of the positive impact of this 
example of peer support and the sharing of information and knowledge by those who have 
‘walked the walk’ is consistent with the results of a qualitative study on peer mentoring in HSCT 
(Rini et al., 2007). Patients in this study reflected that experiential information from patients who 
had survived helped them to feel more prepared for treatment, improved decision-making, 
reduced uncertainty and increased hope. Based on these preliminary findings, there may be value 
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in expanding this additional aspect of patient carer support in HSCT. Likewise, peer mentoring 
provided by experienced carers may be expected to be as valuable as that provided by 
experienced patients. Further research is needed, however, to ascertain the potential positive and 
negative effects of experiential information on patients and carers. 
 
Information satisfaction is an outcome that has been used in previous evaluations of education 
interventions (Gurrud et al., 2001; McQuellon et al., 1998). In our study, satisfaction with 
information was good to begin with and there was no difference in satisfaction levels after 
receiving the intervention. This may be because patients were already satisfied and the increase 
in information did not make patients any more satisfied. Anecdotally, most patients appeared to 
be satisfied with the education provided. In Gurrud et al.’s study (2001) compared the effects of 
providing detailed risk information pamphlets versus a standard information pamphlet to patients 
who were deciding to undergo elective laparoscopy. Patients who received the pamphlet 
containing the information on adverse side effects had higher satisfaction with information. It is 
likely that patients undergoing HSCT are already very aware of the risks associated with 
treatment compared to other illnesses. It is likely that the patient’s specialist has informed the 
patient about their individual prognosis prior to attending the education programme. In addition, 
many participants reported obtaining information from the Internet. It may have been more 
informative if we had measured satisfaction with the education programme generally, instead of 
specific to information. This may have told us more about satisfaction with the education 
programme per se’, as other studies have found increased satisfaction with education in oncology 
(Cartledge & Haaga, 2005; McQuellon et al., 1998; Poroch, 1995). A measurement of what 
patients liked about the education programme day and what they disliked may have been 
informative. Further it would significantly enhance understanding of the role such an education 
programme can play in improving patient and carer experience of critical medical treatment if 
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they could be assessed for whether they felt they had been given too much, too little or the right 
amount of information about specific aspects of that medical treatment. 
 
A fundamental caution that should be noted in interpreting the findings of this research, in 
respect of information satisfaction at least, is the lack of participation of that cohort of patients 
and careers who could have participate in the education programme, more or less conveniently, 
but chose not to. Hypothetically, those patients who did not have major obstacles preventing 
them from attending but who still did not attend may have shown the most benefit from the 
education programme. This is based on an assumption that patients who attend are more likely to 
be ‘information-seeking’ people who already know a lot about HSCT. Whereas those who did 
not take up the offer of education, may not be as well informed. Therefore, non-attending 
patients may have shown the greatest changes on measures such as information satisfaction and 
perhaps even distress and illness perceptions after attending the education programme. At the 
same time, the refusal of this group of people to participate in both the education programme and 
this research may indicate an adaptive coping strategy based upon avoidance of information. On 
the other hand, perhaps this satisfaction with the information they already have or reluctance to 
participate in formally organised and professionally supervised events. Of course, these issues 
are speculative but they suggest interesting avenues for future research. 
 
Illness perceptions have been found to have an important impact on patients’ behaviour and 
emotional reactions in a variety of illness (Weinman & Petrie, 1997). There was no effect of 
education on illness perceptions in our study, although there were changes in some illness beliefs 
over time. For instance, in the short-term patients’ estimation of how long their illness would 
continue became greater with time. Nevertheless, this effect was not seen at 100-day follow-up. 
At this time, patients perceived greater emotional support but felt they had less confidant 
support. The cause of the perceived decrease in confidant support during this time is not clear. 
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Perhaps it is because of the restrictions in contact with other people that can occur during 
recovery in order to control the risk of developing infection. Patients may be secluded from 
family and friends while they are in the acute phase of recovery. One hypothesis is that 
perception of emotional support is less affected by regular contact.  
 
Some studies have found relationships between illness perceptions and adherence to treatment 
regimes and recovery (Weinman & Petrie, 1997). In this study, there was a relationship between 
perception of personal control and survival. Early death from HSCT was associated with lower 
perception of personal control over the illness. Because this is a correlation, this result should be 
interpreted with caution. More research is needed to understand the implications of this result. If 
the result is true there are two potential meanings: (1) people realise the prognosis is worse and 
believe that they have less control accurately or (2) people who believe they have less control are 
less compliant, make poorer lifestyle choices and this impacts their health. Hoodin and 
colleagues (2006) found patients who had optimistic cognitive styles prior to HSCT were more 
likely to have longer survival and better quality of life post HSCT. Again, this finding is 
relational but suggests an issue worth exploring further. 
 
Changing illness perceptions may be useful, particularly if illness beliefs are detrimental to 
emotional functioning and resulting in unhelpful behaviour. However, if illness perceptions are 
realistic (e.g. if patients appreciate the seriousness of their illness) it may not be useful to change 
these perceptions. This may explain why illness perceptions were not affected by the education 
programme. As discussed, patients and carers who participated in this research had most likely 
received a large amount of information prior to the education programme. The information 
provided by the intervention may have corresponded with what patients already knew and thus 
did not result in changed perceptions. For example, most patients believed their treatment could 
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help their illness. This is a positive belief and helpful because it is likely to encourage behaviours 
that support compliance with treatment regimens. 
 
Another outcome of interest in this project was social support. The support of family and carers 
was predicted to be important for HSCT patients because they play such a vital role in the 
recovery of the patients; physically and emotionally. Indeed, consistent social support prior to 
HSCT has been associated with increased survival and better quality of life post-transplant 
(Rodrigue et al., 1999). It was also thought that patients might feel more support with the 
education programme or that there would be indirect benefits to the patients through the 
caregivers receiving the intervention. Surprisingly, there were no changes in patient support as a 
result of education. Perhaps this finding makes sense in light of the lack of influence of the 
education programme on patient or carer psychopathology. If the intervention is increasing 
knowledge but not helping to relieve anxiety or depression, there is unlikely to be changes in 
perception of social support either. Some patients mentioned the benefit of meeting with the 
transplant coordinator and other members of the multidisciplinary team, however, other stressful 
information provided on the day may have cancelled out the impact of this support. In addition, 
the measure of social support specifies family and friends and thus patients may have excluded 
the support provided by the hospital staff. Nevertheless, it would be expected that there would be 
an impact on support provided by the carer who is the primary support person.  
 
Again, since carers of HSCT patients play such an important role and are likely to be 
significantly impacted by the illness, caregiver burden was included as an outcome measure. 
Notwithstanding, there was no impact of education on carers’ burden. Although carer levels of 
distress and anxiety were certainly high in our sample, there was no impact of education on 
distress either. This may reflect the lack of change in caregiver burden also. One would expect 
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that burden would be related to levels of psychopathology and if education is not affecting 
distress, then it is not surprising that perception of burden is also not affected.  
4.5. FUTURE RESEARCH 
4.5.1. STUDY DESIGN 
Suggestions for future directions for research would be to consider including a larger sample size 
to be able to investigate the differences between autologous and allogeneic transplant patients. If 
patients could be contacted directly, it is possible that recruitment would be improved. 
Conducting a multicentre trial would be useful if you could coordinate with the hospitals to have 
the same education programme. It would also be beneficial to assess the long-term outcome of 
the education programme. Adding the intervention to a hospital that does not offer an education 
programme is another way of obtaining a long-term control.  
 
Qualitative follow-up is important to discover what patients and carers understood and valued 
from the education programme. Having attended the education programme it was clear that 
difficult topics were not addressed in detail. When patients asked about their individual risk of 
mortality, the specialist would advise them to speak to their doctor about those sorts of questions. 
The presentation by the clinical psychologist was very superficial in information about distress. 
It did not provide any indication of the levels of distress that patients and/or carers may 
experience. Nor did it suggest strategies to cope or identify important people to speak to in case 
of significant anxiety or depression.  
 
Future research should also consider whether providing the education programme is more 
effective than not providing education or using other models of presentation. The intervention is 
an enormous expense in terms of money and time and only 50% of patients are taking up the 
opportunity. Perhaps there are better and cheaper ways to inform people. Every patient is 
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provided with a book about the transplant. Anecdotally, there appeared to be differences in the 
way this information was received. Some patients and carers found it to be helpful, others found 
it lacking in detail and still others reported that it had too much detail. There were also patients 
and carers who chose not to read it at all. It would be informative to evaluate patients and carer 
use of, and response to, the written information booklet provided. In addition, research should 
investigate preferences for information and other methods of education. Perhaps a combination 
of information delivery methods should be trialled, such as an interactive Internet educational 
programme with staged levels of complexity combined with a subsequent in-person education 
programme. Providing alternate ways of accessing information may be helpful for patients who 
want more information but do not want to read a booklet or attend a public seminar. 
Incorporating the opportunity to meet both health professionals and experienced patients and 
careers for peer support could be another way to support individual patient needs. 
 
An important question yet to be addressed is how to manage those patients and carers who do not 
take up the offer of education. Qualitative information regarding what patients received from the 
education programme day will be useful in this regard and in adjusting the education programme 
so that there is a balance between the need for hospitals and medical professionals to gain 
informed consent and for patients to hear about what is useful and important to them. Further, as 
discussed above, studies of the information receptive needs and biases of those who could have, 
but did not, attend would be useful. 
 
It is well established in the research that there are patients who do not want more information 
(Harris, 1998). If the education programme is provided as a means for the hospital to obtain 
informed consent, are these patients then not giving informed consent? It raises the ongoing 
dilemma of who is responsible for establishing informed consent. If the hospital and treating 
medical professionals carry the burden of responsibility for providing informed consent, or at 
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least should assume that burden in their own self-interest, then there may well be a need to make 
the education more accessible to patients. All patients are sent out a thorough information book 
particular to their transplant type. Yet it is not known which patients and carers are capable of, or 
care to, both read and comprehend the information contained in these books. It is arguable that if 
hospitals and treating medical professionals provide adequate opportunities for patients to 
receive detailed information, it is the patients’ and carer’s responsibility and right to choose how 
much information they would like to receive. It is equally arguable that, while it is the 
responsibility of hospitals and treating medical professionals to provide a readily accessible, 
flexible and adequate treatment education programme, the patient (and even critical caregivers) 
should undertake to participate in education and acknowledge that they have as a condition of 
treatment. This argument maintains that, if a medical treatment should only be administered if 
the patient’s consent is properly informed, then the treatment provider is entitled to make the 
receipt of that treatment, where reasonably practical and possible, conditional upon the patient 
genuinely seeking, and acknowledging, the acquisition of the knowledge. 
4.5.2. PSYCHOSOCIAL SUPPORT 
The fact that patients and carers still had high levels of distress at follow-up indicates that 
information alone is not sufficiently meeting patient and carer needs beyond informed consent. 
Thus, evaluating what psychosocial support is currently available and its effectiveness is another 
avenue for future research in this area. Unfortunately, psychological support was not easily 
available for patients or carers at the hospital. Evaluating the benefits of different treatments at 
different stages of transplantation is another avenue for future research in HSCT. A trial of 
Cognitive Behaviour Therapy (CBT) is recommended based on the results of this study. Illness 
perceptions were found to be associated with increased distress and CBT is effective in 
moderating unhelpful cognitions and behaviour. In other cancer settings CBT has been shown to 
have positive effects on psychosocial and medical outcome measures (Hopko, Bell, Armento, 
  107
Robertson, Mullane, Wolf et al., 2008). Providing CBT prior to transplantation may help patients 
to reduce their distress and improve their experience of treatment. 
4.5.3. DISTRESS 
In order to better target treatment interventions, studies that investigate why patients and carers 
are distressed are needed. Providing carers only with emotional support would not be effective if 
lack of practical and financial support is what is causing them the most concern. Similarly, if 
patients are distressed due to their carers not coping, providing carers with support and treatment 
is likely to be helpful in reducing patient distress more so than only providing patient support. 
4.5.4. DONORS 
Finally, donors information and psychosocial needs seem to have received little attention at least 
in terms of hospital interventions. More information is needed about their experience because the 
strain of the donation of stem cells in HSCT can be substantial. One patient reported that his 
brother felt he was not being given enough information or preparation for his role as a donor. It 
is important to know how donors are coping and what their needs are. A qualitative study would 
be most useful initially in order to assess their experience and concerns. 
4.6. CLINICAL IMPLICATIONS 
One of the main clinical implications of the study is that there seems to be a need for greater 
psychological support for patients and carers. The literature suggests that psychological function 
pre-transplant has a direct effect on post-transplant distress (Broers et al., 2000). In one study, 
psychological distress, sense of personal control and physical health accounted for 50 percent of 
the variance in psychological distress at one-year post-HSCT (Fife et al., 2000). Therefore, it 
would appear that making therapeutic and support services easily accessible to patients and 
carers prior to transplantation would be one of the best ways to improve health and wellbeing. At 
Westmead Hospital, the clinical psychologist’s caseload was stretched between two departments 
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and the waiting list was too long to be functional for HSCT patients who need to be able to 
receive assistance in a timely and effective way. Psychoeducation, supportive therapy, cognitive 
therapy, relaxation training, problem-solving and social skills training, biofeedback, and 
hypnosis are some of the psychological interventions that have been used with cancer patients 
(Hopko et al., 2008). No one intervention has been thoroughly established as the treatment of 
choice for cancer patients to date. A review of evidence-based interventions in the literature  
indicate group therapy, education, structured counselling, cognitive-behavioural therapy, 
communication skills training, and self-esteem training are efficacious in improving patient 
psychological outcomes (Newell, Sanson-Fisher, & Savolainen, 2002). Generally, behaviourally 
based therapies appear to be more effective than supportive therapies. Research studies on 
effective psychological interventions for HSCT patients are few and far between  (Hoodin et al., 
2006). There is preliminary support for mindfulness interventions with HSCT patients (Bauer-
Wu, Sullivan, Rosenbaum, Ott, Powell, McLoughlin et al., 2008). One pilot study has found 
significant decreases in heart and respiratory rates and improvements in symptoms immediately 
before and after each meditation session (Bauer-Wu et al., 2008). However, whether these 
interventions have long-term and broader application is unclear. Due to the medical demands 
placed on HSCT patients, brief and frequent behavioural interventions have been advocated. 
 
A randomized study compared two brief support interventions for 53 cancer patients of varying 
diagnoses (Cunningham & Tocco, 1989). The first group was a psycho-educational or coping 
skills training programme, which included some supportive discussion and the second group was 
a control intervention comprising supportive discussion alone. While patients in both groups 
benefited, the coping skills training group had greater improvements in affect. CBT may be the 
most practical psychological treatment for medical settings and cancer patients because it is 
time-limited and focuses on changing unhelpful behaviours. It can also be effective in increasing 
self-efficacy and sense of “control” over one’s life. This could be helpful for patients who are 
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feeling helpless about their treatment. Hopko et al (2008) found CBT led to significant 
improvements in depression, anxiety, quality of life, and medical outcome measures in depressed 
cancer patients. 
 
In the wider population, CBT and antidepressant medication (ADM) are frequently used in the 
treatment of depression. In medical patients, there may also be a tendency to rely more heavily 
on ADM due to its ease of delivery and cost-effectiveness. Unfortunately, psychologists may not 
be as accessible in hospitals where there may be understaffing. A number of trials have shown 
that ADM is superior to placebo in the treatment of depression (Hollen et al., 2006). ADM tends 
to suppress symptoms for as long as it is maintained but there is no evidence that it helps to 
reduce the underlying cause of symptoms or reduces their risk of recurrence once it is 
terminated. CBT has been shown to be very effective in treating symptoms of anxiety and 
depression. The research on treatment for depression suggests that CBT is at least as effective as 
ADM in reducing acute distress (Hollen, Stewart, & Strunk, 2006). Furthermore, the effect of 
CBT appears to be more enduring than that of ADM. CBT has been shown to be particularly 
effective with individuals who have higher initial levels of depressive symptoms (Cuijpers, van 
Lier, van Straten, & Donker, 2005). Further, since the efficacy of ADM is based on the 
hypothesis that there are biochemical correlates of depression and depression in HSCT may be 
reactive to stressors rather than chemicals, the efficacy of ADM cannot be assumed. 
 
CBT for depression and/or anxiety is a structured therapy that involves collaborative formulation 
that links past experiences with current stressors and draws attention to the relationships between 
thoughts, feelings and behaviours (Beck, Rush, Shaw, & Emery, 1979). Symptom reduction and 
problem solving are argued to be the primary targets of a CBT intervention (Scott, 1996). Clients 
are taught to collect evidence in a systematic fashion in order to offset the influence of 
maladaptive information-processing strategies and to conduct behavioural experiments to test the 
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accuracy of negative beliefs (Hollen et al., 2006). The independent use of strategies taught in 
session is an important aspect of this treatment in recognition of the chronic recurrent nature of 
depression and anxiety. A meta-analysis of studies investigating psychotherapy and 
pharmacotherapy separately and in combination found that the combination of both treatments 
was slightly more effective than either treatment separately (Conte, Plutchik, Wild, & Toksoz, 
1986). 
 
For some patients who were identified as suffering from depression, it was asked whether they 
had any access to treatment. Many replied that they had not received any care. This is not 
surprising given that research indicates hospital nursing staff are not adept at identifying patients 
in need of psychological support. Some patients were on anti-depressant medication prescribed 
by their general practitioner. There are limitations to the effectiveness of medication in providing 
long-term relief from distress. Naturally, there are significant situational causes that explain why 
patients could suffer from anxiety and depression, which makes them good candidates for CBT 
interventions. A major difficulty is that there is little support available in the hospital for 
assessment and intervention. Despite the fact that a clinical psychologist presents in the 
education programme, the reality of the situation is that there are not enough clinicians on staff 
to meet patient needs. Waiting lists are substantial because one psychologist is responsible for 
multiple wards and works part-time. Therefore, the availability of psychological support is low. 
In a perfect system, patients should be regularly and routinely screened for depressive and 
anxiety symptoms. Patients who are identified as needing support should be given the 
opportunity to speak to a psychologist or social worker. This is also necessary for carers, and 
although it may be more difficult to assess carers, it is imperative that they receive attention as 
well given their significant anxiety and distress levels. Regular support groups should be run for 
carers so that they can meet other carers in similar situations. This would provide the opportunity 
for carers without good support networks to discuss their fears, readily acquire coping and 
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performance skills and find ongoing resources which may cumulatively lesson their anxiety and 
increase their effectiveness and role satisfaction. 
4.7. CONCLUSIONS 
Despite the limitations addressed, this study also has a number of strengths. The high proportion 
of clinically significant psychopathology in our patient sample is consistent with the existing 
literature. More importantly, this research adds to the limited knowledge on carer 
psychopathology and burden and highlights their need for support. Preliminary investigation of 
illness perceptions were conducted, identifying important relationships between illness 
perceptions and distress. Finally, this was the first empirical evaluation of an education program 
for HSCT patients and their carers and it found support for the education intervention in 
increasing the primary outcome variable of knowledge. Notably the intervention was successful 
in increasing knowledge without increasing patient or carer distress or care burden. At the same 
time, simply increasing knowledge is not enough to reduce patient and carer distress and thus 
further research is needed to identify what aspects of the education program are helpful for 
patients and what are unhelpful and how such programmes may be further developed so as to 
enhance their reception by patients and carers. This study seeks to consider and contribute some 
suggestions in that regard. Exploring illness perceptions further may identify patients who are 
more likely to experience significant distress. Finally, treatment interventions, such as individual 
or group CBT, are needed to help patients and carers cope with the significant stress of HSCT.  
 
 
 
